Viral Enteric Infections

Taxonomy and Virology of Enteric Viruses

The taxonomic landscape of enteric viruses is extraordinarily diverse, encompassing members from multiple viral families that have convergently evolved the capacity to infect and replicate within the gastrointestinal tract. These pathogens span a remarkable phylogenetic breadth, including RNA viruses (e.g., Caliciviridae, Reoviridae, Astroviridae, Coronaviridae, Picornaviridae) and DNA viruses (e.g., Adenoviridae, Parvoviridae, Circoviridae), each with distinct virion architecture, genome organization, and replication strategies that dictate their host range, tropism, and pathogenic potential [6, 19, 30]. Understanding the foundational virology of these agents is not merely an academic exercise; it provides the molecular framework for diagnostic development, therapeutic intervention, and epidemiological surveillance, particularly given the immense global burden of acute gastroenteritis, which remains a leading cause of morbidity and mortality among children under five years of age in low- and middle-income countries [27, 28].

Major Viral Families Associated with Enteric Disease

Caliciviridae are non-enveloped, positive-sense single-stranded RNA (+ssRNA) viruses, with Norovirus and Sapovirus representing the most clinically significant genera in humans. Noroviruses are classified into at least ten genogroups (GI–GX), with GI, GII, and GIV primarily infecting humans. Within GII, genotype 4 (GII.4) is historically the most predominant globally, responsible for recurrent pandemic waves due to its rapid antigenic evolution [8, 28]. The norovirus genome, approximately 7.5–7.7 kb in length, encodes three open reading frames (ORFs): ORF1 translates a large polyprotein cleaved by the viral 3C-like protease into non-structural proteins (including RNA-dependent RNA polymerase, RdRp), while ORF2 and ORF3 encode the major capsid protein VP1 and the minor structural protein VP2, respectively. The VP1 protein, particularly its protruding (P) domain, contains critical epitopes and histo-blood group antigen (HBGA) binding interfaces that mediate host attachment and strain susceptibility. This binding specificity is genetically determined by host FUT2 and FUT3 gene polymorphisms, a linkage that has been epidemiologically associated with differential susceptibility to norovirus and rotavirus infections, and has been implicated in the pathogenesis of inflammatory bowel disease [22]. Notably, murine norovirus (MNV), which belongs to genogroup GV, has served as an indispensable small animal model for dissecting norovirus biology, viral persistence, and host immune interactions, particularly given its ability to establish chronic infections, a phenomenon now recognized as a feature of human norovirus as well [9, 29, 33].

Reoviridae, specifically the genus Rotavirus, represents a leading cause of severe dehydrating gastroenteritis in infants and young animals worldwide [17, 19, 27]. Rotaviruses are non-enveloped, triple-layered particles with a segmented genome of 11 double-stranded RNA (dsRNA) segments. This segmented architecture facilitates genetic reassortment during co-infection, a mechanism that drives enormous antigenic diversity and the emergence of novel strains capable of evading pre-existing immunity. The outer capsid proteins VP7 (glycoprotein) and VP4 (protease-sensitive spike protein) define the G- and P-genotypes, respectively; over 36 G-types and 51 P-types have been identified globally, though a limited subset (e.g., G1P[7], G2P[4], G3P[7], G4P[7], G9P[7], G12P[7]) predominates in human disease [12, 28]. Rotavirus group A is the most epidemiologically significant, though groups B, C, and H also infect humans and animals. The virus selectively targets and destroys mature villous enterocytes in the small intestine, leading to villous atrophy, malabsorptive diarrhea, and activation of the enteric nervous system, which drives secretory diarrhea via the viral enterotoxin NSP4 [16, 17].

Adenoviridae, within the genus Mastadenovirus, includes two major enteric types in humans: adenovirus types 40 and 41 (species F). These are non-enveloped, double-stranded DNA (dsDNA) viruses with icosahedral capsids and characteristic fiber projections that mediate attachment to host cell receptors. Enteric adenoviruses are a significant cause of pediatric gastroenteritis, ranking second or third after rotavirus and norovirus in prevalence [1, 12, 14]. Unlike respiratory adenoviruses, enteric serotypes 40 and 41 exhibit fastidious growth in conventional cell culture, a challenge that has historically complicated diagnosis and study. Their genome (~34 kb) encodes early (E) and late (L) transcription units, with the late proteins comprising the major capsid components, hexon, penton base, and fiber. The fiber knob domain determines tropism, and for enteric adenoviruses, this appears to facilitate binding to enterocytes, though the precise receptor remains incompletely defined. The role of enteric adenoviruses has also been explored as a potential risk factor for intussusception in children, though causality remains unconfirmed [14]. In veterinary medicine, canine adenovirus types 1 and 2 (CAV-1, CAV-2) are significant contributors to enteric and respiratory disease in dogs, respectively, and are often included in multiplex diagnostic panels designed to differentiate among several canine viral pathogens [2, 25].

Astroviridae are non-enveloped, +ssRNA viruses with a distinctive star-shaped surface morphology when visualized by electron microscopy. Human astroviruses (classic Mamastrovirus species) are primarily associated with mild, self-limiting gastroenteritis in children, the elderly, and immunocompromised individuals, though recent metagenomic studies have uncovered a vast diversity of novel astroviruses in both human and animal hosts [10, 12]. The astrovirus genome (~6.8 kb) contains three ORFs: ORF1a and ORF1b encode non-structural proteins including the RdRp, while ORF2 encodes the capsid protein precursor, which undergoes proteolytic processing to yield mature capsid proteins. Notably, astroviruses have been implicated in trans-kingdom immune interactions; murine astrovirus can complement immunodeficiency in mice, protecting against norovirus and rotavirus infection via an interferon-lambda (IFN-λ)-dependent mechanism, thereby highlighting the virome’s capacity to modulate host susceptibility to other enteric pathogens [11].

Coronaviridae are enveloped, +ssRNA viruses with the largest known RNA genomes (~27–32 kb). Several coronaviruses are established enteric pathogens across multiple species. In humans, while seasonal coronaviruses (OC43, HKU1, NL63, 229E) typically cause mild respiratory illness, SARS-CoV-2 has been extensively documented to infect the gastrointestinal tract, with viral RNA and antigen detected in stool, and with evidence of enteric nervous system involvement contributing to gut dysfunction [3, 5]. Enteric coronaviruses of veterinary importance are numerous and economically impactful. Transmissible gastroenteritis virus (TGEV) of swine, canine enteric coronavirus (CCoV), feline enteric coronavirus (FECV), and bovine coronavirus are all alphacoronaviruses or betacoronaviruses that replicate in intestinal epithelial cells, causing villous atrophy and diarrhea [16, 20, 24]. Of particular note, FECV is the precursor to feline infectious peritonitis virus (FIPV), a lethal systemic disease that arises from specific mutations in the viral spike (S) gene acquired during enteric replication, allowing the virus to gain tropism for macrophages and disseminate systemically [32]. Similarly, CCoV has undergone substantial recombination in the spike protein N-terminal domain (NTD), leading to the emergence of more pathogenic variants and evidence of systemic dissemination [20]. Coronaviruses encode a characteristic set of non-structural proteins, including the papain-like protease (PLpro) and 3C-like protease (3CLpro), which are essential for polyprotein processing and are targets for antiviral drug development.

Picornaviridae includes Enterovirus species such as echoviruses and coxsackieviruses, which can cause gastroenteritis but are more commonly associated with systemic disease including myocarditis, meningitis, and encephalitis [21]. Enteroviruses are non-enveloped, +ssRNA viruses with a genome of approximately 7.5 kb that is translated as a single polyprotein, subsequently cleaved by viral proteases into structural (capsid) and non-structural proteins. The capsid is composed of four proteins (VP1–VP4), with VP1, VP2, and VP3 forming the external surface and VP4 lining the interior. Their resistance to low pH and proteolytic enzymes in the gastrointestinal tract facilitates survival through the stomach and efficient infection of enterocytes and M cells in Peyer’s patches. The recent development of macrophage-augmented intestinal organoids (MaugOs) has demonstrated that echoviruses 1 and 6 can productively infect human intestinal epithelium and replicate efficiently, though they do not trigger the same degree of inflammatory cytokine release observed with rotavirus or coronavirus infection, indicating differential engagement of host innate immune pathways [3].

Virological Features of Canine and Feline Enteric Viruses

In canine medicine, the most clinically relevant enteric viruses include canine parvovirus type 2 (CPV-2), canine coronavirus (CCoV), and canine adenovirus (CAV). CPV-2, a member of Parvoviridae (genus Protoparvovirus), is a non-enveloped, linear ssDNA virus with a genome of approximately 5.2 kb. Its replication requires host cell DNA polymerase and is therefore dependent on actively dividing cells, targeting the highly proliferative crypt epithelium of the small intestine, leading to severe hemorrhagic gastroenteritis and leukopenia [2, 4, 31]. CPV-2 has undergone antigenic drift, with the original type 2 being replaced globally by variants 2a, 2b, and 2c, which exhibit altered host range and enhanced pathogenicity, particularly in dogs. The VP2 capsid protein is the primary determinant of host range and antigenicity, and it is the target for both diagnostic PCR assays and vaccine-induced immunity [2]. CCoV, an alphacoronavirus, has historically been associated with mild enteritis in dogs, but recent reports of lethal systemic infections have elevated its significance as an emerging pathogen. The virus’s propensity for recombination in the spike gene, particularly between different CCoV serotypes and with feline or porcine coronaviruses, generates novel variants with altered tropism and increased virulence [20]. Canine circovirus (CanineCV), a relatively newly identified member of Circoviridae, is a small, non-enveloped circular ssDNA virus. Its role as a primary enteric pathogen remains uncertain; while viral DNA is detected in dogs with gastroenteritis, it is frequently found in co-infections with CPV-2 or CCoV, and experimental evidence for causality is lacking [25, 31]. Molecular diagnostic tools, particularly multiplex PCR assays targeting conserved genomic regions (e.g., the VP2 gene for CPV-2, the endoribonuclease nsp15 gene for CCoV, and the 52K gene for CAV), have greatly facilitated simultaneous detection of these pathogens and are now standard in veterinary diagnostics [2, 25].

Viral Structure, Entry Mechanisms, and Replication Strategies

A unifying virological principle among enteric viruses is their remarkable stability in the face of hostile gastrointestinal conditions. Non-enveloped viruses (rotavirus, norovirus, astrovirus, adenovirus, parvovirus) are intrinsically resistant to acid, bile salts, and proteolytic enzymes, allowing them to transit the stomach and reach the small intestine with intact infectivity [7, 30]. Enveloped viruses like coronaviruses are more labile but are still transmitted effectively, particularly when cloaked within vesicles that provide physical protection, as has been recently demonstrated for rotavirus and norovirus. These vesicle-cloaked viral clusters, shed in stool as aggregates within extracellular vesicles of exosomal or plasma membrane origin, represent highly efficient transmission units that deliver a high multiplicity of infection to the next host and enhance disease severity [23]. This finding fundamentally alters the traditional view of fecal-oral transmission, suggesting that free virions are not the sole nor necessarily the most important infectious unit.

Cell entry mechanisms are diverse. Rotavirus utilizes VP8* (the distal portion of VP4) to bind to sialic acid or HBGAs, while VP7 facilitates attachment. Subsequent uncoating is triggered by trypsin cleavage of VP4 into VP5* and VP8*, and the viral particle enters the cell via direct membrane penetration or endocytosis. Norovirus attachment is mediated by the VP1 P domain binding to HBGAs, with entry occurring via clathrin-mediated endocytosis. Adenoviruses use the fiber knob to engage the coxsackie-adenovirus receptor (CAR) or, for enteric types, an unidentified receptor, followed by integrin-mediated internalization via the penton base RGD motif [14]. Parvoviruses like CPV-2 bind to the transferrin receptor on feline or canine cells, a key determinant of host range.

Replication strategies are equally varied. Rotavirus, with its segmented dsRNA genome, transcribes and replicates entirely within the host cell cytoplasm, using viral inclusion bodies (viroplasms) as replication factories. The 11 segments are transcribed into +ssRNA, which serves as mRNA as well as a template for minus-strand synthesis to produce progeny dsRNA genomes. This segmented nature allows for genetic reassortment, a major driver of diversity. Norovirus replication occurs in the cytoplasm, with the genomic RNA serving as mRNA for ORF1 translation; the polyprotein is cleaved by the viral 3C-like protease, and a subgenomic RNA is produced for ORF2 and ORF3 translation. The RdRp (NS7) is error-prone, generating substantial genetic diversity that fuels immune evasion. Coronaviruses employ an elegant but complex replication cycle: upon entry and uncoating, the +ssRNA genome is translated to produce a large polyprotein that is cleaved into 16 non-structural proteins (nsps), many of which assemble into a membrane-associated replication-transcription complex (RTC) that produces a nested set of subgenomic mRNAs via discontinuous transcription. This mechanism allows for expression of structural and accessory proteins from the 3′ end of the genome. The viral RNA proofreading exoribonuclease (nsp14) confers a relatively high fidelity for an RNA virus, but recombination is frequent due to template switching during replication, a critical feature for coronavirus evolution and emergence [20, 24].

The host-virus interface at the molecular level is exquisitely regulated by antiviral signaling pathways. Interferon-lambda (IFN-λ, type III IFN) has emerged as a dominant, non-redundant antiviral cytokine in the intestinal epithelium, largely because epithelial cells express the IFN-λ receptor (IFNLR1) at high levels while maintaining only low levels of the type I IFN receptor (IFNAR). This compartmentalized system allows epithelial cells to respond primarily to IFN-λ, while lamina propria hematopoietic cells rely on type I IFNs, thereby limiting systemic inflammation [13, 18, 26]. Many enteric viruses have evolved countermeasures to subvert this response. For instance, rotavirus NSP1 degrades the host interferon regulatory factors (IRFs) to suppress IFN induction, while norovirus NS1/2 inhibits IFN-λ signaling. The E3 ubiquitin ligase TRIM29 has been shown to target NLRP6 and NLRP9b for K48-linked ubiquitination and degradation, thereby suppressing IFN-λ and IL-18 production in intestinal epithelial cells, effectively limiting the host’s ability to control enteric RNA virus infection and inflammation [15]. These molecular arms races underscore the co-evolutionary struggle between viruses and their hosts.

Molecular Pathogenesis of Viral Enteric Infections

The molecular pathogenesis of viral enteric infections has been profoundly redefined by recent integrative studies, moving beyond a simplistic model of direct viral cytopathicity to a sophisticated understanding of a multi-kingdom interface. This interface involves dynamic interactions between the virus, the intestinal epithelial barrier, the host innate and adaptive immune systems, and the complex microbial ecosystem (bacteria, phages, fungi, and helminths) that constitutes the gut microbiome. The outcome of infection, ranging from asymptomatic shedding to severe, life-threatening gastroenteritis, is determined by the molecular interplay at this nexus.

The Intestinal Epithelial Barrier: A Battleground of Restriction and Subversion

The intestinal epithelium is a single-cell monolayer that constitutes the first physical and immunological barrier to enteric viruses [7]. This barrier is composed of diverse, specialized epithelial cell types, including enterocytes, goblet cells, Paneth cells, tuft cells, and microfold (M) cells overlying Peyer's patches. Each cell type presents a unique molecular environment for viral replication. Goblet cells, for instance, are the primary producers of the mucus barrier, a complex network of mucin glycoproteins that can both trap viral particles and, paradoxically, be exploited by some viruses for attachment and entry [39].

The host antiviral response within the epithelium is critically dependent on a compartmentalized interferon (IFN) system. Intestinal epithelial cells (IECs) express high levels of the interferon-λ (IFN-λ) receptor but only low levels of functional type I IFN (IFN-α/β) receptors [18]. This specialization was elegantly demonstrated using reovirus infection, where IFN-λ receptor-deficient mice exhibited robust viral replication in gut epithelial cells, whereas IFN-α/β receptor-deficient mice showed replication restricted to the lamina propria [18]. Thus, IFN-λ acts as the primary antiviral defense system of the gut mucosa, serving as a frontline gatekeeper to control infection at the epithelial surface without triggering the potentially inflammatory systemic type I IFN response [13, 18, 26]. The importance of IFN-λ is underscored by its role in controlling persistent murine norovirus (MNV) infection; administration of IFN-λ can cure persistent infection even in the absence of adaptive immunity [33].

Enteric viruses, however, have evolved sophisticated molecular strategies to subvert this IFN-λ shield. The E3 ubiquitin ligase TRIM29 has been identified as a critical host factor that is co-opted by enteric RNA viruses, including rotavirus and encephalomyocarditis virus (EMCV). Mechanistically, TRIM29 promotes K48-linked polyubiquitination and subsequent proteasomal degradation of the pattern recognition receptors NLRP6 and NLRP9b in IECs [15]. This targeted degradation dampens the production of both IFN-λ and interleukin-18 (IL-18), thereby suppressing the antiviral and inflammatory signaling cascades that would normally restrict viral replication and recruit protective intraepithelial lymphocytes [15]. This illustrates a direct molecular mechanism by which viruses can dismantle the host's primary epithelial defense.

Beyond IFN signaling, the epithelium also deploys a formidable arsenal of antimicrobial peptides, particularly α-defensins, which are constitutively secreted by Paneth cells. While these peptides are often considered broad-spectrum antivirals, the molecular reality is more nuanced. In a paradigm-shifting study using primary stem-cell-derived enteroids (mini-guts), enteric α-defensins were shown to paradoxically enhance infection by mouse adenovirus type 2 (MAdV-2). This enhancement occurred via a receptor-independent mechanism, where α-defensins facilitated the binding of viral particles to the cell surface, effectively acting as a molecular bridge for infection [37]. This proviral effect was physiologically relevant, as wild-type mice shed more MAdV-2 in their feces than mice lacking functional α-defensins [37]. This suggests that some enteric viruses have evolved to co-opt these host defense molecules to promote their own transmission.

The Virome and Viral Co-Infections: A Complex Molecular Ecosystem

The enteric virome is a dynamic and diverse community composed not only of pathogenic viruses but also of commensal eukaryotic viruses and bacteriophages [30]. The molecular interactions within this virome can have profound effects on disease pathogenesis. A landmark study demonstrated that murine astrovirus, a typically benign component of the virome, could complement immunodeficiency in mice to protect against subsequent infection by murine norovirus and rotavirus [11]. This protection was horizontally transferable via co-housing and fecal transplantation and was absolutely dependent on IFN-λ signaling in gut epithelial cells [11]. This reveals that a non-pathogenic virus can molecularly "prime" the host's intestinal antiviral state, a phenomenon with major implications for understanding susceptibility to co-infections.

Clinically, viral co-infections are highly prevalent, detected in up to 8.3% of virus-positive children with acute gastroenteritis, with rotavirus-norovirus being the most common combination [12]. While the molecular mechanisms governing these co-infections are poorly understood, quantitative data suggest that rotavirus loads are often higher in co-infected patients, hinting at synergistic interactions that could enhance replication or transmission [12]. The nature of these interactions, whether direct, through receptor competition or complementation, or indirect, through modulation of the host immune response, remains a critical area for future research [6].

Trans-Kingdom Interactions: The Microbiota as a Master Regulator

The most transformative advance in our understanding of enteric viral pathogenesis is the recognition of trans-kingdom interactions, where the bacterial microbiota profoundly regulates viral infection [30]. The bacterial microbiota is now understood to be a critical arbiter of enteric virus replication, persistence, and transmission. For example, the persistence of murine norovirus in the gut is strictly dependent on the presence of the bacterial microbiota. Antibiotic treatment abrogates persistent infection, an effect that is reversed by replenishing bacteria [33]. This effect requires the host IFN-λ receptor, Stat1, and Irf3, indicating that the microbiota normally acts to suppress a tonic IFN-λ signal that would otherwise control the virus [33].

The molecular basis for this regulation is multifaceted. The bacterial product lipopolysaccharide (LPS) has been shown to directly bind to enteric viruses like poliovirus and norovirus, enhancing their stability and attachment to host cells [30]. However, the effect of bacterial components is not universally proviral; peptidoglycan-associated surfactin from Bacillus subtilis is a potent viricidal compound that can directly disrupt the integrity of enveloped viruses, including coronaviruses [40]. This highlights the highly conditional and specific nature of these interactions.

Crucially, these effects are mediated through microbiota-derived metabolites. Short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, are among the most important of these signaling molecules. SCFAs can exert potent antiviral effects by priming the host's innate immune system. The herbal monomer ginsenoside Rg3, for example, enriches SCFA-producing Blautia spp. in the gut. These SCFAs, acting via the GPR43 receptor on macrophages, enhance intracellular Ca2+ signaling and MAVS-dependent mitochondrial DNA release, which in turn activates the cGAS-STING-IRF3 axis to induce type I IFN [34]. This demonstrates a specific molecular cascade whereby a dietary compound, through the manipulation of the microbiome and its metabolites, can enhance systemic antiviral immunity. In a different context, SCFA supplementation has been shown to partially reverse the gut barrier dysfunction and dysbiosis induced by influenza A virus infection, thereby reducing susceptibility to secondary bacterial enteric infections [38].

Conversely, other metabolites can have proviral effects. Bile acids, for instance, can generally regulate interferon responses, but their effect is highly virus-specific [36]. The flavonoid desaminotyrosine also modulates IFN responses, further illustrating the concept that the molecular outcome of a viral infection is the sum of competing signals from a complex metabolite milieu [36].

Secretory immunoglobulins (sIg), another product of the host-microbiota interaction, also play a paradoxical role. Contrary to the expectation that sIg would be universally protective, polymeric immunoglobulin receptor (pIgR) knockout mice, which lack sIg in their intestinal lumen, show reduced infection by both MNV and reovirus. This reduced susceptibility was linked to elevated levels of IFN-γ and iNOS in the gut, which were dependent on the presence of the microbiota [9]. This suggests that natural sIg normally promote infection by modifying the host's immune tone through interaction with the microbiota, a finding that turns a central tenet of mucosal immunology on its head.

Cellular Sites of Persistence and Immune Evasion

The molecular pathogenesis of enteric viruses also involves the establishment of immune-privileged niches. Murine norovirus, for instance, can establish a chronic, persistent infection characterized by continuous shedding in stool. This persistence is not due to T cell exhaustion; virus-specific CD8+ tissue-resident memory (Trm) T cells remain highly functional during chronic infection [29]. Instead, the virus evades immune surveillance by replicating in an immune-privileged enteric niche where it is hidden from these potent T cells. Pre-existing Trm cells could only detect the virus for approximately 72 hours post-challenge, after which viral replication became sequestered and "ignorant" of the adaptive immune response [29]. The identity of this cellular sanctuary and the molecular signals that govern viral entry into and exit from this niche remain to be fully defined.

Furthermore, the mode of viral egress itself has been molecularly redefined. It was long thought that enteric viruses were shed as individual, naked virions. However, a significant fraction of rotaviruses and noroviruses in stool are actually shed as clusters of multiple viral particles enclosed within extracellular vesicles of exosomal or plasma membrane origin [23]. These "vesicle-cloaked virus clusters" are highly stable and deliver a high multiplicity of infection to the receiving host, dramatically enhancing disease severity [23]. This discovery fundamentally alters our molecular understanding of the fecal-oral transmission unit and identifies vesicles as a critical, previously underappreciated determinant of viral pathogenesis.

Implications for the Inflamed Gut

In hosts with underlying inflammatory bowel disease (IBD), the molecular pathogenesis of enteric viral infections is further complicated. While common enteric viruses like adenovirus, rotavirus, and norovirus are frequently detected in patients with acute severe ulcerative colitis, their detection does not appear to exacerbate the severity of the flare or clinical outcomes such as the need for colectomy [1]. This suggests that in a heavily inflamed intestinal environment, the relative contribution of a superimposed acute viral enteritis to the total pathology may be minor. However, the role of specific viruses like cytomegalovirus (CMV) in IBD is well-established, highlighting that the molecular context of the host's pre-existing inflammation profoundly dictates the clinical significance of any given enteric viral infection [35]. Mutations in host genes like FUT2, which encodes a fucosyltransferase responsible for the expression of histo-blood group antigens (ligands for norovirus and rotavirus), are also associated with IBD risk, suggesting that genetic susceptibility to viral binding may be a co-factor in disease pathogenesis [22].

Epidemiology and Transmission Dynamics

The epidemiology of viral enteric infections is a complex tapestry woven from pathogen biology, host susceptibility, environmental factors, and the intricate interplay of the intestinal microbiome. Understanding the transmission dynamics of these agents is paramount for designing effective control strategies, predicting outbreak potential, and mitigating the substantial global burden of acute gastroenteritis. This section provides an exhaustive analysis of the prevalence, distribution, and transmission mechanisms of major enteric viruses, drawing upon the latest research to illuminate the multifaceted nature of their spread.

Global and Regional Prevalence Patterns

Viral enteric infections represent a leading cause of morbidity and mortality worldwide, with a disproportionate impact on children under five years of age in low- and middle-income countries (LMICs) [27]. The etiological landscape is dominated by a core group of pathogens, including rotavirus, norovirus, astrovirus, and enteric adenoviruses. Surveillance data from South Korea, spanning 2013 to 2019, revealed that enteric viruses were detected in 30.1% of acute gastroenteritis cases in children ≤5 years, with norovirus (15.2%) and group A rotavirus (9.7%) being the most prevalent [28]. This pattern is echoed globally, though the relative contribution of each virus varies by region, age group, and season. Rotavirus, prior to widespread vaccine introduction, was the leading cause of severe diarrheal disease in children, a burden now partially mitigated but still substantial in areas with low vaccine coverage [27]. Norovirus, conversely, has emerged as the predominant cause of acute gastroenteritis across all age groups in developed countries, responsible for both sporadic cases and massive outbreaks in closed settings like cruise ships, hospitals, and schools [8, 28].

The epidemiology of these infections is not static. The COVID-19 pandemic, and the associated implementation of non-pharmaceutical interventions (NPIs) such as lockdowns, social distancing, and enhanced hand hygiene, profoundly altered the transmission dynamics of enteric pathogens. A nationwide observational study in China reported dramatic reductions in the test-positive rates of all major enteric viruses during the first pandemic year (2020) compared to pre-pandemic averages (2012–2019). Relative decreases were striking: 71.75% for adenovirus, 58.76% for norovirus, and 53.50% for rotavirus A [41]. This phenomenon, observed globally, underscores the critical role of human-to-human contact and environmental contamination in the transmission of these viruses. The rebound of rotavirus A observed in North China after September 2020, but not in the South, highlights the potential for rapid resurgence as NPIs are lifted, particularly in pediatric populations whose immunity may have waned during the period of reduced circulation [41]. This suggests a delicate balance where temporary suppression can lead to larger, more intense future epidemics.

Transmission Pathways: The Fecal-Oral Route and Beyond

The primary transmission route for enteric viruses is the fecal-oral pathway, encompassing person-to-person contact, consumption of contaminated food or water, and contact with fomites [21]. The resilience of these non-enveloped viruses (e.g., rotavirus, norovirus, adenovirus) in the environment is a key factor in their efficient spread. They can persist for extended periods on surfaces, in water, and on food, resisting common disinfectants. Wastewater-based epidemiology (WBE) has emerged as a powerful tool to monitor community-level circulation of these viruses, revealing that viral shedding is far more prevalent than clinical case reporting suggests. Studies in Japan and France have demonstrated the near-ubiquitous presence of norovirus and other enteric viruses in raw wastewater throughout the year, even during periods of low clinical incidence [8, 42]. This indicates a substantial reservoir of asymptomatic and mild infections that contribute to ongoing transmission. For instance, a WBE study in Japan estimated that norovirus infections exceeded reported acute gastroenteritis cases by 3.2-fold in summer-autumn and a staggering 23.9-fold in winter-spring, highlighting the vast iceberg of undetected infections driving the epidemic [8].

A paradigm-shifting discovery in the transmission dynamics of enteric viruses is the role of vesicle-cloaked viral clusters. Research has demonstrated that rotaviruses and noroviruses are shed in stool not only as individual virions but also as clusters enclosed within extracellular vesicles of exosomal or plasma membrane origin [23]. These vesicle-cloaked clusters remain intact during fecal-oral transmission, delivering a high multiplicity of infection to the next host. This mechanism enhances infectivity and disease severity compared to free viruses, fundamentally altering our understanding of the optimal infectious unit [23]. This finding has profound implications for disinfection strategies and the development of antivirals, which must now target not only free virions but also these protected, high-inoculum clusters.

While the fecal-oral route is paramount, the potential for aerosol transmission of enteric viruses in healthcare settings is an area of growing concern. Procedures such as vomiting, toilet flushing, and even patient care activities can generate bioaerosols containing infectious viruses [43]. Norovirus, in particular, is notorious for its ability to cause explosive outbreaks through aerosolized vomitus. The role of viral bioaerosols in nosocomial infections is likely underestimated, as recovering infectious virus from air samples remains technically challenging [43]. This transmission route poses a significant risk to vulnerable populations, including the immunocompromised, the elderly, and children, who are overrepresented in hospital settings.

The Microbiome as a Master Regulator of Transmission and Susceptibility

The intestinal microbiota is no longer viewed as a passive bystander but as a critical determinant of enteric virus infection, replication, and transmission. This transkingdom interaction, where viruses, bacteria, and the host immune system engage in a complex dialogue, is a central theme in modern virology [30]. The bacterial microbiota can have both proviral and antiviral effects, often mediated by specific metabolites.

Proviral Effects of the Microbiota: A landmark study demonstrated that persistent murine norovirus (MNV) infection requires the presence of the gut microbiota. Treatment with broad-spectrum antibiotics prevented persistent MNV infection, an effect that was reversed by replenishing the bacterial community [33]. This proviral effect is mediated, at least in part, through the suppression of type III interferon (IFN-λ) signaling. The microbiota dampens the host's innate antiviral response, creating a permissive environment for viral persistence [33]. Furthermore, bacterial components can directly enhance viral infectivity. For example, enteric α-defensins, antimicrobial peptides produced by Paneth cells, have been shown to enhance mouse adenovirus 2 (MAdV-2) infection by promoting receptor-independent binding to host cells [37]. Similarly, natural secretory immunoglobulins (sIg), traditionally considered protective, have been found to paradoxically promote MNV and reovirus infection by modulating the microbiota-driven immune environment, leading to reduced IFN-γ levels [9]. These findings challenge classical immunological dogma and reveal that the host's own defense mechanisms can be co-opted by viruses in the context of a specific microbial community.

Antiviral Effects of the Microbiota and Metabolites: Conversely, specific bacterial metabolites can exert potent antiviral effects. Short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, are produced by the fermentation of dietary fiber by commensal bacteria. These metabolites have emerged as key regulators of viral infections. Ginsenoside Rg3, a herbal monomer, has been shown to enrich SCFA-producing Blautia spp., which in turn protect against enteric virus infection by inducing type I interferon (IFN-I) responses in macrophages via the MAVS-IRF3-IFNAR signaling pathway [34]. The mechanism involves SCFA-mediated activation of GPR43 signaling, leading to enhanced intracellular Ca²⁺-dependent mitochondrial DNA release and activation of the cGAS-STING-IFN-I axis [34]. Acetate, in particular, has been shown to potently inhibit virus-induced inflammatory responses in macrophage-augmented intestinal organoids (MaugOs) infected with rotavirus and SARS-CoV-2, while differentially affecting viral replication in different cell types [3]. This highlights the nuanced role of metabolites, which can simultaneously suppress damaging inflammation and modulate viral load. The protective role of SCFAs extends beyond enteric viruses; influenza A virus infection, which causes respiratory disease, can indirectly impair gut barrier function and reduce SCFA production, thereby increasing susceptibility to secondary enteric bacterial infections [38]. This demonstrates a systemic axis where a respiratory infection can alter the gut microenvironment, influencing the dynamics of enteric pathogens.

Host Factors and Transmission Dynamics

Host genetics and physiological status also play a critical role in transmission dynamics. The expression of histo-blood group antigens (HBGAs) on intestinal epithelial cells, which are controlled by the FUT2 and FUT3 genes, serves as attachment factors for norovirus and rotavirus. Polymorphisms in these genes, which determine secretor status, are associated with differential susceptibility to infection and have been linked to inflammatory bowel disease (IBD) [22]. This genetic variation creates a heterogeneous host population, influencing the effective reproductive number (R₀) of the virus within a community.

The use of proton pump inhibitors (PPIs), which suppress gastric acid production, has been identified as a risk factor for acquiring enteric viral infections. A large matched cohort study found that continuous PPI use was associated with an 81% increased risk of acute gastroenteritis during periods of high enteric virus circulation [46]. This is likely due to the reduction of the stomach's acid barrier, which normally serves as a first line of defense against ingested pathogens, allowing more viruses to survive transit to the intestine and initiate infection. This finding has significant public health implications, given the widespread and often inappropriate use of PPIs.

Co-infections and the Role of the Virome

Enteric viral co-infections, where a host is simultaneously infected with two or more viruses, are increasingly recognized as common events, detected in up to 8.3% of virus-positive children with acute gastroenteritis [12]. The most frequent combination is rotavirus with norovirus [12]. The clinical significance of these co-infections is complex and not fully understood. While some studies suggest they may be associated with increased disease severity, others find no difference [6]. The use of viral load as a proxy measure has revealed that rotavirus is often detected at higher levels in co-infected patients, suggesting a potential synergistic interaction [12]. The gut virome, the collection of all viruses inhabiting the intestine, is a dynamic ecosystem. Beyond causing acute disease, resident viruses can modulate host immunity. For instance, a specific strain of murine astrovirus was found to complement immunodeficiency in mice, protecting them against subsequent norovirus and rotavirus infection in an IFN-λ-dependent manner [11]. This demonstrates that the virome is not merely a collection of pathogens but an integral component of the intestinal ecosystem that can shape the outcome of subsequent infections.

Transmission in Special Populations and Settings

The epidemiology of enteric viral infections is profoundly influenced by the host's immune status. In immunocompromised individuals, such as those with HIV/AIDS or IBD, these infections can be more severe, prolonged, and difficult to clear [35, 44]. Patients with IBD, including Crohn's disease and ulcerative colitis, are at increased risk for viral infections, and superimposed enteric viral infections can complicate disease management [1, 35]. Interestingly, a study on acute severe ulcerative colitis found that while viral enteropathogen infection was common (14.9%), it did not appear to alter disease severity or outcomes, suggesting a complex relationship between the virus, the inflamed gut, and the host response [1].

In veterinary medicine, the transmission dynamics of enteric viruses in livestock and companion animals have significant economic and zoonotic implications. Canine parvovirus (CPV-2), canine coronavirus (CCoV), and canine adenovirus (CAV) are major causes of gastroenteritis in dogs, with CPV-2 being specifically associated with diarrheal cases [4, 25]. The emergence of recombinant CCoV strains with novel spike proteins, linked to increased disease severity, highlights the evolutionary potential of these viruses [20]. In neonatal calves and piglets, rotavirus and coronavirus infections are a leading cause of mortality, with transmission heavily reliant on passive lactogenic immunity from colostrum and milk [16, 17]. The World Organisation for Animal Health (WOAH) recognizes the significant impact of these infections on livestock productivity and food security. In rabbits, enteric viruses like lapine rotavirus and rabbit enteric coronavirus are recognized as contributors to the multifactorial enteritis complex, a major cause of morbidity in commercial rabbitries [45]. The transmission of these agents is facilitated by high-density housing and the resistance of the viruses to environmental degradation.

Clinical Manifestations and Disease Severity

The clinical spectrum of viral enteric infections spans an extraordinarily broad continuum, ranging from entirely asymptomatic viral shedding to fulminant, life-threatening gastroenteritis. This heterogeneity is governed by a complex interplay of viral virulence factors, host immune status, age, nutritional state, the composition of the intestinal microbiota, and the presence of underlying comorbidities. Understanding the nuanced manifestations and determinants of disease severity is paramount for accurate clinical diagnosis, prognostication, and the rational deployment of therapeutic interventions. The clinical presentation is not merely a reflection of viral cytopathology but is profoundly shaped by the host’s inflammatory and immune responses, which can themselves become drivers of pathology.

Spectrum of Clinical Presentation

The cardinal manifestation of enteric viral infection is acute gastroenteritis, characterized by the sudden onset of diarrhea, which may be watery, non-bloody, and voluminous. Vomiting, nausea, abdominal cramps, and low-grade fever are frequent accompanying features. The severity, however, is highly variable. In immunocompetent adults, infections with norovirus or rotavirus often result in a self-limited illness lasting 24 to 72 hours, with symptoms rarely requiring medical intervention beyond oral rehydration. In stark contrast, the same pathogens can precipitate severe, dehydrating illness in the very young, the elderly, and the immunocompromised. The World Health Organization (WHO) recognizes diarrheal diseases as a leading cause of mortality in children under five years of age, with rotavirus historically being the predominant etiological agent before the widespread introduction of vaccines. The clinical severity is often graded using scoring systems such as the Vesikari scale, which integrates the frequency and duration of diarrhea and vomiting, the degree of fever, and the need for rehydration therapy.

A critical and often underappreciated aspect of viral enteric infections is the phenomenon of asymptomatic infection. Wastewater-based epidemiology studies have demonstrated that the burden of norovirus infections in the community far exceeds the number of clinically reported cases, with estimates suggesting that for every reported case, there may be several-fold more undetected, asymptomatic, or mildly symptomatic infections [8]. This asymptomatic carriage has profound implications for transmission dynamics, as individuals shedding virus without clinical illness can unknowingly perpetuate outbreaks, particularly in closed settings such as nursing homes, cruise ships, and hospitals.

Determinants of Disease Severity: Host Factors

Age and Immune Status: Age is one of the most powerful determinants of disease severity. Neonates and infants possess an immature immune system and a developing intestinal barrier, rendering them exquisitely susceptible to severe dehydration and electrolyte imbalances from even modest fluid losses. In this population, rotavirus infection can lead to life-threatening hypernatremic dehydration and metabolic acidosis. Conversely, the elderly often experience more severe norovirus infections due to immunosenescence and a higher prevalence of comorbidities. The most profound and protracted disease, however, occurs in immunocompromised individuals. Patients with primary immunodeficiencies, those undergoing chemotherapy, solid organ or hematopoietic stem cell transplant recipients, and individuals with advanced HIV/AIDS are at extreme risk for chronic, severe, and disseminated enteric viral infections [35, 44]. In these patients, viruses such as norovirus, astrovirus, and enteric adenovirus can establish persistent infections lasting months to years, characterized by chronic diarrhea, malabsorption, profound weight loss, and a significantly increased risk of mortality. The loss of adaptive immunity, particularly T-cell and B-cell function, cripples the host’s ability to clear the virus, leading to unchecked viral replication and ongoing enterocyte damage.

Underlying Gastrointestinal Pathology: The clinical trajectory of a viral enteric infection is dramatically altered in the context of pre-existing inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. In patients with acute severe ulcerative colitis (ASUC), a superimposed viral enteric infection is a common clinical concern. However, a retrospective study of 147 ASUC patients found that while viral enteropathogens (adenovirus 40/41, rotavirus, norovirus) were detected in 14.9% of cases, their presence did not significantly alter key severity metrics, including admission C-reactive protein levels, Mayo endoscopic subscore, length of hospital stay, requirement for rescue therapy, or colectomy rate [1]. This suggests that in the setting of profound, pre-existing colonic inflammation, the additional insult from a common enteric virus may be masked or that the host response is already maximally activated. Conversely, other research indicates that enteric viruses can act as triggers for IBD flares. Genome-wide association studies have linked polymorphisms in FUT2 and FUT3 genes, which encode enzymes responsible for synthesizing histo-blood group antigens that serve as ligands for norovirus and rotavirus, with an increased risk of IBD [22]. This suggests that host genetic susceptibility to viral attachment may modulate the risk of virus-induced inflammatory exacerbations. Furthermore, disruptions in autophagy within Paneth cells and perturbations in Th1 and Th17 inflammatory pathways following enteric virus infection have been implicated in IBD pathogenesis [22].

The Role of the Microbiota and Metabolites: The intestinal microbiota is a critical arbiter of enteric virus pathogenesis. The bacterial microbiome can both promote and protect against viral infection. For instance, the persistence of murine norovirus in the gut is dependent on the presence of the bacterial microbiota; antibiotic treatment can eradicate persistent infection, an effect that is dependent on interferon-λ (IFN-λ) signaling [33]. This proviral effect is mediated, in part, by bacterial components and metabolites. Conversely, microbiota-derived metabolites, particularly short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate, exert potent immunomodulatory effects. SCFAs have been shown to inhibit virus-induced inflammatory responses in macrophage-augmented intestinal organoids while differentially affecting viral replication [3]. The ginsenoside Rg3, a herbal monomer, can enrich SCFA-producing Blautia species, which in turn protect against enteric virus infection by inducing type I interferon responses in macrophages via the MAVS-IRF3-IFNAR signaling pathway, a process involving the cGAS-STING axis [34]. This intricate transkingdom control highlights that the severity of an enteric viral infection is not a fixed property of the virus but is dynamically regulated by the metabolic state of the gut ecosystem [30]. Disruption of this ecosystem, such as through the use of proton pump inhibitors (PPIs), which alter gastric pH and the intestinal microbiome, has been associated with a nearly two-fold increased risk of acute gastroenteritis during periods of high enteric virus circulation [46].

Determinants of Disease Severity: Viral and Pathophysiological Factors

Viral Tropism and Cytopathology: The primary target for most enteric viruses is the mature villous enterocyte of the small intestine. Infection leads to enterocyte death, either through direct viral cytolysis or through the induction of apoptosis. This results in villous atrophy, crypt hyperplasia, and a loss of absorptive surface area, leading to the classic pathophysiology of osmotic diarrhea. The severity of villous atrophy correlates directly with the clinical severity of diarrhea. Rotavirus, for example, is highly efficient at infecting and destroying enterocytes, leading to profound fluid and electrolyte loss. The non-structural protein NSP4 of rotavirus acts as an enterotoxin, further exacerbating fluid secretion by triggering a calcium-dependent signaling pathway that opens chloride channels, independent of the structural damage [16].

Viral Load and Co-infections: The magnitude of viral replication, often reflected in fecal viral load, is a key driver of disease severity. Higher viral loads are generally associated with more severe symptoms and a greater risk of transmission. The phenomenon of viral co-infections, where two or more enteric viruses are detected simultaneously, is increasingly recognized due to the use of multiplex PCR panels. Co-infections are common, with rotavirus-norovirus being the most frequent combination, detected in up to 70.6% of co-infected children in some studies [12]. The impact of co-infections on disease severity is complex and not fully resolved. Some studies suggest that co-infected patients may have higher viral loads of certain pathogens (e.g., rotavirus) and potentially more severe clinical presentations, while others find no significant difference in outcomes compared to single infections [6, 12]. The outcome likely depends on the specific viral combination, the host’s immune status, and potential viral interference or synergy.

Novel Mechanisms of Pathogenesis and Transmission: Recent discoveries have unveiled sophisticated mechanisms by which enteric viruses enhance their own infectivity and severity. A landmark study demonstrated that rotaviruses and noroviruses are shed in stool not only as free virions but also as vesicle-cloaked clusters. These clusters, enclosed within extracellular vesicles of exosomal or plasma membrane origin, deliver a high multiplicity of infection to the next host. These vesicle-cloaked viruses are more virulent than free viruses, as they protect the viral payload from environmental degradation and host immune defenses, leading to increased disease severity in recipient animals [23]. This finding fundamentally alters our understanding of the optimal infectious unit for fecal-oral transmission.

Furthermore, the host’s own innate immune molecules can be subverted to promote infection. Enteric α-defensins, antimicrobial peptides secreted by Paneth cells that typically function as broad-spectrum antivirals, have been shown to paradoxically enhance infection by mouse adenovirus type 2 (MAdV-2). In primary intestinal enteroids, the presence of an α-defensin gradient, mimicking the physiological state in the small intestinal lumen, significantly increased MAdV-2 infection by facilitating receptor-independent binding of the virus to the cell surface. This effect was confirmed in vivo, where wild-type mice shed significantly more virus than mice lacking functional α-defensins [37]. Similarly, natural secretory immunoglobulins (sIg), long considered a first line of humoral defense, have been shown to promote murine norovirus and reovirus infection. In the absence of sIg (in pIgR knockout mice), infection was significantly reduced, an effect linked to increased levels of the antiviral cytokine IFN-γ [9]. These findings illustrate a sophisticated evolutionary arms race where viruses have adapted to exploit components of the host’s innate mucosal defense system.

Severe and Atypical Clinical Manifestations

Beyond typical gastroenteritis, enteric viruses can cause a spectrum of severe and atypical manifestations. Intussusception, a condition where a segment of the intestine telescopes into an adjacent segment, causing obstruction and ischemia, has been linked to enteric viral infections, particularly adenovirus and, historically, rotavirus. A case-control study in Egypt found that enteric adenovirus (types 40 and 41) and asymptomatic rotavirus infection were detected at higher frequencies in children with intussusception compared to controls, although a definitive causal link remains to be fully established [14]. This association was a critical concern during the development of early rotavirus vaccines.

Systemic dissemination is a hallmark of severe disease in immunocompromised hosts and with certain viral strains. Canine enteric coronavirus (CCoV), traditionally associated with mild gastroenteritis, has emerged as a cause of lethal systemic disease in dogs, with evidence of viral dissemination to multiple organs [20]. In humans, enteroviruses can cause severe systemic disease, including encephalitis, meningitis, myocarditis, and hepatitis [21]. The ability of viruses to breach the intestinal barrier and spread systemically is often facilitated by a compromised immune system or by direct infection of intestinal immune cells. For instance, feline enteric coronavirus (FECV) can infect immune cells even in the absence of robust intestinal replication, and mutations arising during this cell-associated viremia can give rise to the highly lethal feline infectious peritonitis virus (FIPV) [32].

Remote organ effects are another dimension of disease severity. Respiratory infections, such as influenza A virus (IAV), can profoundly impact the gut. IAV infection in mice leads to intestinal injury, dysbiosis, reduced SCFA production, and compromised gut barrier function, which in turn favors secondary enteric bacterial infections with pathogens like Salmonella Typhimurium [38, 47]. This demonstrates that a viral infection at a distant mucosal site can indirectly increase the severity of enteric disease through systemic immune modulation and disruption of the gut ecosystem. The enteric nervous system (ENS) is also a target and a source of viral infection. SARS-CoV-2 and other viruses can infect enteric neurons and glial cells, potentially contributing to the gastrointestinal symptoms seen in COVID-19 and other viral illnesses, and may even serve as a reservoir for viral persistence and a conduit for CNS involvement [5].

In summary, the clinical manifestations and severity of viral enteric infections are the product of a dynamic and multi-layered interaction between the virus, the host’s genetic and immunological landscape, the resident microbiota, and the broader physiological state of the organism. The spectrum of disease is vast, from silent shedding to life-threatening systemic illness, and our understanding of the molecular and ecological determinants of this spectrum continues to evolve, revealing new targets for therapeutic intervention and prevention.

Diagnostic Approaches: From Stool Microscopy to Multiplex PCR

The diagnostic landscape for viral enteric infections has undergone a profound metamorphosis over the past several decades, transitioning from rudimentary morphological assessments to sophisticated, high-throughput molecular platforms capable of unmasking the intricate polymicrobial dynamics of the intestinal virome. This evolution is not merely a technical upgrade; it represents a fundamental shift in our conceptualization of enteric disease, moving from a pathogen-centric model of single-agent causality to a systems-level understanding that embraces co-infections, host–microbiota–virus transkingdom interactions, and the nuanced role of viral burden in clinical outcomes. The trajectory from stool microscopy to multiplex PCR embodies this paradigm shift, each successive layer of technological refinement revealing previously obscured layers of complexity in the pathogenesis, epidemiology, and clinical management of viral gastroenteritis.

The Foundational Era: Limitations of Light Microscopy and Electron Microscopy

In the earliest days of diagnostic virology, the identification of enteric viruses relied almost exclusively on direct visualization. Light microscopy of stool specimens, while invaluable for detecting ova, parasites, and bacterial pathogens, is fundamentally inadequate for visualizing viruses due to their sub-micron dimensions. The application of electron microscopy (EM) in the 1970s and 1980s represented the first true breakthrough for viral enteric diagnostics, enabling the direct visualization of characteristic viral morphologies, the wheel-like appearance of rotavirus, the small round structured particles of norovirus, and the icosahedral architecture of adenoviruses, in stool homogenates [10, 17]. This technique was instrumental in the initial discovery and taxonomic classification of many enteric viruses and remains a gold standard for identifying novel or unexpected viral agents.

However, EM suffers from critical limitations that preclude its use as a front-line diagnostic tool. It requires expensive, specialized equipment and highly trained personnel, rendering it impractical for most clinical settings, particularly in low-resource environments where the burden of enteric disease is highest. Furthermore, EM has a relatively high limit of detection, typically requiring (10^5) to (10^6) viral particles per gram of stool for reliable identification. This insensitivity means that low-level viral shedding, which is now recognized as a common feature of both asymptomatic carriage and chronic infections, is routinely missed [33]. The technique also provides no information on viral genotype, serotype, or viability, critical parameters for epidemiological surveillance, vaccine efficacy studies, and outbreak investigations. The advent of immune electron microscopy (IEM), which uses specific antisera to aggregate virions, modestly improved sensitivity but could not overcome the fundamental throughput and scalability barriers. As such, the EM era, while foundational, left clinicians and epidemiologists with a profoundly incomplete picture of the true prevalence and diversity of enteric viral infections.

Immunological and Antigen-Based Methods: ELISA and Immunochromatography

The development of enzyme-linked immunosorbent assays (ELISA) and lateral-flow immunochromatographic assays marked a significant leap forward, providing rapid, relatively inexpensive, and scalable tools for detecting viral antigens in stool. These techniques, which rely on antibodies directed against conserved viral structural proteins, became the workhorses of enteric virus diagnostics throughout the 1990s and early 2000s. Commercial ELISA kits for rotavirus, enteric adenovirus (types 40/41), astrovirus, and, to a lesser extent, norovirus, were deployed widely in clinical laboratories and were instrumental in large-scale epidemiological studies, including the pivotal pre-licensure trials of rotavirus vaccines [14, 22, 27]. Their simplicity, a colorimetric readout that could be assessed visually without specialized instrumentation, made them suitable for use in diverse settings, from central hospital labs to field-based surveillance in low- and middle-income countries.

The strength of antigen-based methods lies in their speed (results in 15–30 minutes for immunochromatographic strips) and their ability to detect acute infections with high viral loads. In pediatric populations with high-titer rotavirus or adenovirus shedding, these tests demonstrate excellent sensitivity and specificity. However, their limitations are substantial. For norovirus, the high genetic diversity and antigenic drift among genogroups and genotypes have historically hampered the development of broadly reactive, sensitive antigen detection assays. Many commercial norovirus ELISA kits have shown disappointing sensitivity (often below 50-70%) compared to molecular methods, leading to significant underestimation of disease burden [28]. Similarly, antigen tests perform poorly in detecting viral co-infections, which are now recognized as a common phenomenon. Studies examining children with acute gastroenteritis have found co-infection rates exceeding 8% among virus-positive patients, with the most frequent combination being rotavirus with norovirus [12]. Antigen-based methods, being monoplex by nature, would require separate tests for each suspected pathogen, a costly and time-consuming approach that fails to capture the full etiological picture in a single assay.

Moreover, these immunological methods provide no information on viral genotype or subtype, which is essential for molecular epidemiology, tracking of emerging strains, and linking clinical outcomes to specific viral lineages. For instance, the emergence of new rotavirus genotypes or norovirus GII.4 variants with pandemic potential cannot be monitored using antigen detection alone [20, 28]. The cycle threshold (Ct) values from real-time PCR have also been used as a proxy for viral load, revealing that rotavirus is often detected at significantly higher levels in co-infected patients compared to single infections, a nuance entirely invisible to antigen-based platforms [12]. The inability of immunological assays to discriminate between viable infectious virus and non-infectious antigenic debris further complicates their interpretation, particularly in convalescent patients or those with prolonged shedding.

The Molecular Revolution: Singleplex Real-Time PCR

The introduction of polymerase chain reaction (PCR), and specifically real-time quantitative PCR (qPCR), transformed the diagnostic landscape for enteric viruses by offering orders of magnitude greater sensitivity and the capacity for genotyping. Singleplex qPCR assays, which amplify and detect a specific conserved genomic region of a single virus (e.g., the VP2 gene of canine parvovirus-2, the NSP3 gene of rotavirus, or the ORF1-ORF2 junction of norovirus), quickly became the reference standard for virological diagnosis [2, 8, 12]. The exquisite sensitivity of qPCR, capable of detecting as few as 10–100 viral genome copies per reaction, revealed that viral shedding in stool is far more common and persistent than previously appreciated. This finding has profound implications: it suggests that asymptomatic carriers and individuals with low-level chronic infections are a significant reservoir for transmission, a phenomenon well-documented for murine norovirus where persistence in the gut is dependent on the bacterial microbiota and is counteracted by interferon-λ signaling [33].

The advantages of PCR over antigen detection are manifold. It allows for precise genotyping through sequencing of amplicons or the use of type-specific probes, enabling the tracking of viral evolution and the identification of outbreak strains. For norovirus, genotyping is particularly critical given the emergence of pandemic GII.4 variants that exhibit altered antigenicity and transmissibility [28]. PCR also facilitates the detection of viruses that are difficult to culture or for which reliable antigen tests are unavailable, such as sapovirus, astrovirus, and the newly recognized canine circovirus [31]. Furthermore, quantitative PCR provides a continuous measure of viral load (via Ct values), which can be correlated with disease severity, transmission potential, and response to therapy. In the context of acute severe ulcerative colitis, for example, the detection of adenovirus 40/41, rotavirus, or norovirus GI by fecal multiplex PCR does not appear to alter disease severity at presentation, need for rescue therapy, or colectomy rate, suggesting that the mere presence of viral RNA does not equate to clinical causality [1]. This insight underscores a critical limitation of ultra-sensitive molecular diagnostics: the ability to detect nucleic acid does not necessarily indicate viable, replicating virus or active disease, and clinical interpretation must be contextualized by viral load, host immune status, and the presence of other potential pathogens.

The deployment of qPCR within surveillance networks, such as the national EnterNet system in South Korea, has provided unprecedented insights into the seasonality and age distribution of enteric viruses. Data from 31,750 cases in children ≤5 years old over a seven-year period revealed that norovirus was the most prevalent pathogen (15.2%), followed by group A rotavirus (9.7%), with winter and spring peaks, respectively [28]. The ability to conduct such large-scale, standardized molecular surveillance was simply not feasible in the antigen era. However, the singleplex approach remains labor-intensive and costly when multiple pathogens must be tested for individually, a limitation that becomes increasingly untenable given the high rates of co-infection. The recognition that coinfections are the rule rather than the exception, whether between viruses [6, 12], between viruses and bacteria [47], or between viruses and parasites [4], has driven the field inexorably toward multiplexed solutions.

The Pinnacle of Syndromic Diagnosis: Multiplex PCR Panels

The development of multiplex PCR (mPCR) panels represents the apotheosis of the molecular diagnostic trajectory for viral enteric infections. These assays co-amplify multiple target genes in a single reaction by employing carefully designed primer sets that target conserved regions unique to each virus, often combined with internal amplification controls to monitor for inhibition. The resulting amplicons are discriminated either by size (conventional mPCR with gel electrophoresis) or by sequence-specific fluorescent probes (real-time multiplex platforms). The power of this approach lies in its ability to provide a comprehensive syndromic diagnosis from a single stool specimen, simultaneously detecting a panel of viruses, bacteria, and parasites [1, 6, 25].

The design of an effective mPCR assay demands meticulous optimization to avoid primer–primer interactions, differential amplification efficiencies, and competition for reagents, which can lead to false negatives for low-titer targets in the presence of high-titer co-infectants. Studies in canine enteric virology have demonstrated successful multiplexing for canine parvovirus-2 (CPV-2), canine coronavirus (CCoV), and canine adenovirus (CAV) by targeting the VP2, endoribonuclease nsp15, and 52K genes, respectively, achieving a detection limit of (1 \times 10^4) viral copies and 100% coincidence with singleplex PCR [2]. Similar mPCR systems have been developed for canine respiratory and enteric viruses, enabling simultaneous detection of up to seven viral agents, including circovirus, which is associated with acute gastroenteritis primarily when found in co-infections with other enteric viruses [25, 31]. The ability to detect such polymicrobial signatures is not merely a technical curiosity; it has direct clinical relevance. For instance, canine circovirus infection correlates with acute gastroenteritis only when associated with other enteric viruses, suggesting a synergistic or facilitative role in pathogenesis rather than a primary etiological one [31].

The clinical application of mPCR in human medicine has yielded equally transformative insights. The retrospective study of acute severe ulcerative colitis patients demonstrating a 14.9% positivity rate for viral enteropathogens (adenovirus 40/41, rotavirus, norovirus GI) using a commercial fecal multiplex PCR panel [1] exemplifies how syndromic testing can rapidly assess the contribution of viruses to complex inflammatory conditions. Previously, such infections in IBD patients were likely underdiagnosed, with clinicians focusing on Clostridium difficile and cytomegalovirus. The multiplex approach provides a comprehensive virological, bacteriological, and parasitological profile, allowing for a more rational deployment of antimicrobial and immunosuppressive therapies. Critically, the study's finding that viral infection did not alter disease severity or outcomes highlights that detection does not equal causation, a nuance that clinicians must navigate when interpreting mPCR results in immunocompromised or chronically inflamed hosts.

From a public health perspective, multiplex PCR has revolutionized surveillance by revealing the true burden of viral co-infections. Data from an 11-year pediatric gastroenteritis study in Italy, where 8.3% of virus-positive patients had co-infections, predominantly rotavirus–norovirus (70.6%) and rotavirus–astrovirus (9.6%), could only be reliably captured through syndromic molecular testing [12]. The use of Ct values as a proxy for viral load in this study further demonstrated that rotavirus is generally shed at higher levels in co-infected patients, raising intriguing questions about viral interference, synergism, or differences in host susceptibility that were previously inaccessible. The capacity to link viral load, co-infection patterns, and clinical severity through multiplex PCR data is now informing vaccine efficacy studies and outbreak investigations. The observation that enteric viral co-infections may influence vaccine responses, as hypothesized for oral rotavirus and polio vaccines in low-income settings [6, 27], underscores the need for diagnostic tools that can capture the full virological context of each infection.

Emerging and Integrated Platforms: From Wastewater to Organoids

The diagnostic horizon extends well beyond the clinical specimen. Wastewater-based epidemiology (WBE) has emerged as a powerful complementary approach, leveraging the fact that enteric viruses are shed in high concentrations in stool and can be concentrated and quantified from municipal sewage. Reverse transcription-quantitative PCR (RT-qPCR) for norovirus GI and GII in wastewater, with subsequent incorporation into mass balance equations using Monte Carlo simulation, has enabled the back-estimation of community infection rates that far exceed those captured by clinical surveillance. In a Japanese study, estimated norovirus infections exceeded reported acute gastroenteritis cases by 3.2-fold in Summer-Autumn and 23.9-fold in Winter-Spring, revealing a vast reservoir of undiagnosed, often asymptomatic infections [8]. The consistent detection of norovirus RNA in wastewater throughout the year, even during summer months with low clinical incidence, underscores the endemicity of these viruses and the limitations of passive clinical surveillance. WBE is now being integrated with clinical sequencing to track the circulation of specific viral genotypes, including enterovirus D68 and hepatitis A and E viruses, providing real-time, population-level data that can inform public health interventions [42]. This approach represents a diagnostic paradigm shift from individual patient-based testing to community-based surveillance, offering a cost-effective means to monitor the emergence of novel variants, assess the impact of non-pharmaceutical interventions (such as those implemented during the COVID-19 pandemic, which dramatically reduced enteric virus positivity rates [41]), and guide vaccination strategies.

Parallel to these advances in molecular detection, the field is witnessing the development of next-generation ex vivo infection models that promise to refine our diagnostic and therapeutic capabilities. Human intestinal organoids (enteroids) and macrophage-augmented organoids (MaugOs) have been established as innovative platforms for studying virus–host interactions, evaluating antiviral compounds, and even assessing viral infectivity [3, 37]. These models can recapitulate critical aspects of the intestinal environment, including the presence of mucus, epithelial polarization, and immune cell interactions. For example, enteroids have demonstrated that enteric α-defensins, antimicrobial peptides secreted by Paneth cells, can enhance infection by mouse adenovirus-2 (MAdV-2) by facilitating receptor-independent binding to the cell surface, a finding that accurately predicted increased viral shedding in wild-type mice compared to defensin-deficient mice [37]. Similarly, MaugOs have revealed that acetate, a short-chain fatty acid produced by gut bacteria, potently inhibits virus-induced inflammatory responses while differentially affecting viral replication in macrophages versus organoids [3]. These systems move beyond simple detection of viral nucleic acid to provide functional data on viral replication competence, cell tropism, and the impact of the host microenvironment. As these organoid-based assays become standardized and scalable, they could serve as a next-generation diagnostic adjunct, distinguishing between viable, pathogenic virus and inert nucleic acid, a distinction that PCR alone cannot make. The integration of such functional assays with multiplex molecular diagnostics could yield a comprehensive picture of both the presence and the pathogenic potential of enteric viruses in a given specimen, finally bridging the gap between molecular detection and clinical relevance.

Therapeutic Interventions and Supportive Care for Viral Enteric Infections

The management of viral enteric infections necessitates a multifaceted approach that addresses not only the direct antiviral effects against the etiologic agent but also the complex interplay between the host immune response, the intestinal microenvironment, and the indigenous microbiota. Therapeutic strategies must be tailored to the specific pathogen, the immunological status of the host, and the severity of clinical disease, ranging from mild, self-limiting gastroenteritis to life-threatening dehydration and systemic complications, particularly in neonates, the elderly, and immunocompromised individuals. The following sections delineate the current paradigm of therapeutic interventions, emphasizing the biological underpinnings that guide clinical decision-making and the emergence of novel, targeted strategies informed by recent mechanistic insights.

Supportive Care and the Maintenance of Intestinal Homeostasis

The cornerstone of management for acute viral gastroenteritis remains aggressive supportive care, primarily focused on fluid and electrolyte resuscitation to counteract the profound losses resulting from vomiting and diarrhea. Oral rehydration therapy (ORT), formulated according to WHO guidelines, is the first-line intervention for mild to moderate dehydration, leveraging the sodium-glucose cotransport mechanism in the small intestine to facilitate water absorption. In severe cases, particularly in young children and those with compromised mucosal integrity, intravenous fluid replacement is essential to prevent hypovolemic shock and metabolic acidosis. Concurrently, nutritional support should be maintained, with early reintroduction of age-appropriate feeds, including breastfeeding, which provides passive immunity via secretory immunoglobulin A (sIgA) and other bioactive factors that can modulate the host response to infection [19]. The role of zinc supplementation in reducing the duration and severity of diarrheal episodes is well-established, although its precise antiviral mechanism remains under investigation.

Beyond rehydration, the use of nonspecific antidiarrheal agents, such as loperamide, is generally contraindicated in viral enteritis, particularly when invasive bacterial pathogens have not been ruled out, as they may prolong pathogen excretion and increase the risk of systemic complications. The evidence for probiotics remains equivocal, with some strains showing modest benefit in reducing diarrheal duration, but the heterogeneity of study designs and the lack of robust mechanistic data in the context of specific viral infections preclude universal recommendation. The systemic impact of severe enteric infection extends beyond the gastrointestinal tract; for instance, influenza A virus infection has been shown to impair gut barrier properties and reduce the production of microbiota-derived short-chain fatty acids (SCFAs), favoring secondary enteric bacterial infections [38]. Supplementation with SCFAs, such as acetate and propionate, in murine models of influenza-associated gut dysbiosis enhanced intestinal barrier integrity and reduced translocation of enteric pathogens like Salmonella enterica serovar Typhimurium, suggesting a potential adjunctive therapy for managing secondary bacterial complications following severe viral enteritis [38]. Furthermore, the indiscriminate use of proton pump inhibitors (PPIs) has been associated with an elevated risk of acute gastroenteritis during periods of high enteric virus circulation, likely due to the reduction of gastric acid barrier function, which normally inactivates ingested viruses [46]. Clinicians should therefore exercise caution in prescribing PPIs during outbreaks of norovirus or rotavirus and reconsider their necessity in hospitalized patients at risk of nosocomial infection [43, 46].

Antiviral and Immunomodulatory Strategies: Targeting the Host-Virus Interface

The development of specific antiviral agents against enteric viruses has historically lagged behind that for respiratory or systemic pathogens, largely due to the self-limiting nature of many infections and the challenges of targeting viruses that replicate within the complex intestinal milieu. However, the recognition of persistent infections, particularly with norovirus in immunocompromised hosts, and the significant morbidity associated with severe rotavirus disease have driven research into targeted therapies. Interferon-lambda (IFN-λ, type III interferon) has emerged as a critical regulator of intestinal antiviral immunity, with a compartmentalized action that is largely restricted to epithelial cells, in contrast to the systemic effects of type I interferons (IFN-α/β) [13, 18, 26]. The intestinal epithelium exhibits low expression of functional IFN-α/β receptors, rendering them primarily responsive to IFN-λ, which is induced following viral infection and acts in a paracrine manner to establish an antiviral state in neighboring enterocytes [18]. This system is particularly relevant for controlling persistent infections; for instance, murine norovirus (MNV) persistence in the gut is determined by the interplay between the bacterial microbiota and IFN-λ signaling, and treatment with recombinant IFN-λ can effectively cure persistently infected mice in an adaptive-immune-independent manner [33]. This has profound implications for human norovirus infections, which can establish long-term shedding in immunocompromised patients and contribute to nosocomial outbreaks. The therapeutic potential of pegylated IFN-λ is currently under clinical investigation for chronic viral hepatitis and may be repurposed for enteric infections, although careful dosing is required to avoid excessive inflammation, as IFN-λ also drives the recruitment of protective CD8+ T cells [29].

The innate immune response to enteric viruses is tightly regulated by host factors that viruses may subvert to their advantage. The E3 ubiquitin ligase TRIM29 has been identified as a key negative regulator of antiviral signaling in intestinal epithelial cells. TRIM29 promotes the K48-linked ubiquitination and degradation of NLRP6 and NLRP9b, two NOD-like receptors critical for the activation of inflammasome responses and the production of IFN-λ and interleukin-18 (IL-18) in response to enteric RNA viruses such as rotavirus and encephalomyocarditis virus [15]. By degrading these sensors, TRIM29 dampens the host antiviral response and facilitates viral replication and intestinal inflammation. Consequently, targeting TRIM29 with specific inhibitors could represent a novel therapeutic strategy to unlock endogenous IFN-λ and inflammasome activity, thereby enhancing viral clearance and reducing inflammation [15]. This approach is particularly compelling for severe rotavirus infections in neonatal and pediatric populations, where the host response is immature.

Microbiota-Directed Therapeutics: Harnessing the Transkingdom Interplay

A paradigm-shifting insight from the past decade is the profound influence of the intestinal microbiota and its metabolites on enteric virus infection and immunity [30]. The bacterial microbiome can both promote and inhibit viral replication, depending on the specific virus and the metabolic context. For instance, the gut microbiota is required for the persistence of MNV, as antibiotic treatment ablates chronic infection in an IFN-λ-dependent manner [33]. This suggests that therapeutic modulation of the microbiota could be exploited to disrupt viral persistence. Conversely, specific microbial metabolites can exert potent antiviral effects. The short-chain fatty acid acetate, a primary fermentation product of commensal bacteria, has been shown to potently inhibit virus-induced inflammatory responses in macrophage-augmented intestinal organoids (MaugOs) infected with rotavirus, coronavirus OC43, and SARS-CoV-2, without directly inhibiting viral replication in all cell types [3]. Acetate acts via GPR43 signaling in macrophages to enhance intracellular calcium- and MAVS-dependent mitochondrial DNA release, which in turn activates the cGAS-STING-IFN-I axis, priming the antiviral state [34]. This provides a mechanistic basis for using SCFAs or SCFA-producing probiotics (e.g., Blautia spp.) as adjunctive therapy to temper excessive inflammation and bolster antiviral immunity [34, 38].

The herbal monomer ginsenoside Rg3 exemplifies another approach to microbiota-directed therapy by enriching SCFA-producing Blautia species in the gut, thereby conferring protection against enteric viruses in germ-free and antibiotic-treated mice [34]. These findings highlight the potential of prebiotics or specific dietary interventions to reshape the microbial ecosystem toward a state that is less permissive for viral infection. However, the relationship is complex, as microbial components can also be proviral. Enteric α-defensins, antimicrobial peptides secreted by Paneth cells, enhance infection by mouse adenovirus type 2 (MAdV-2) by promoting receptor-independent viral binding to enterocytes, a mechanism that may be evolutionarily conserved for certain viruses [37]. Similarly, natural secretory immunoglobulins (sIg), typically considered protective, have been shown to promote norovirus and reovirus infection by altering microbial immune sensing, leading to reduced interferon-gamma (IFN-γ) levels [9]. Thus, any therapeutic intervention targeting the microbiota must be carefully calibrated to avoid inadvertently enhancing viral entry or replication. The development of synthetic bacterial consortia or defined metabolic cocktails (e.g., acetate/propionate) that selectively boost antiviral immunity without providing substrates for proviral interactions represents a promising avenue for future research [3, 30, 34].

Novel Biologics, Targeted Antibodies, and Combination Therapies

The emergence of single-domain antibodies (sdAbs), also known as nanobodies, offers a new class of therapeutics against enteric viruses. Derived from the variable domains of camelid heavy-chain antibodies, sdAbs are significantly smaller than conventional monoclonal antibodies, enabling them to access cryptic epitopes on viral surface proteins that are often inaccessible to larger immunoglobulins [48]. They exhibit high stability against the harsh conditions of the gastrointestinal tract, including low pH and proteolytic enzymes, making them amenable to oral administration. Currently, sdAbs are under development against a range of viral targets, including norovirus and rotavirus, where they can neutralize viral particles by blocking attachment to histo-blood group antigens (HBGAs) or by disrupting the viral capsid [48]. While no sdAbs have yet received clinical approval for enteric infections, their potential for low-cost production and robust activity positions them as a future cornerstone of antiviral therapy, particularly in resource-limited settings where oral, stable formulations are highly desirable.

For enveloped viruses, such as coronaviruses, the discovery that bacterial peptidoglycan-associated surfactin, a cyclic lipopeptide antibiotic produced by Bacillus subtilis, possesses broad virucidal activity is of significant interest. Surfactin disrupts virion integrity, rendering enveloped viruses like SARS-CoV-2, influenza, and Ebola non-infectious in a dose- and temperature-dependent manner [40]. Although surfactin itself may be challenging to administer systemically due to toxicity, its mechanism of action inspires the development of synthetic lipopeptide analogs that could be used as topical or luminal antivirals to decontaminate the gastrointestinal tract during active infection, potentially reducing fecal-oral transmission [23, 40]. The observation that vesicle-cloaked virus clusters, rather than individual viral particles, represent the optimal infectious unit for fecal-oral transmission of rotavirus and norovirus further underscores the need for therapeutics that can disrupt these lipid-encased aggregates [23]. Antivirals targeting the host exosomal pathway or lipid metabolism could, in theory, prevent the formation of these hyper-infectious clusters.

The most rational therapeutic strategy for complex enteric infections likely involves a combination approach, simultaneously targeting viral replication and the host inflammatory response. Proof-of-concept studies in MaugOs have demonstrated that combining an antiviral agent with either an anti-inflammatory regimen or acetate can effectively inhibit both viral replication and the associated cytokine storm, a critical consideration for viruses like SARS-CoV-2 that can trigger severe intestinal inflammation [3]. This is particularly relevant for managing enteric viral infections in patients with inflammatory bowel disease (IBD), where superimposed viral infections can complicate the clinical picture. Notably, in acute severe ulcerative colitis, infection with common viral enteropathogens (adenovirus, rotavirus, norovirus) was frequent (14.9%) but did not significantly alter disease severity, the need for rescue therapy, or colectomy rates [1]. This suggests that while viral detection is important for surveillance, aggressive antiviral therapy may not be necessary in all cases, and management should continue to focus on the underlying IBD. However, in immunocompromised patients, such as those with HIV/AIDS or post-transplant, persistent enteric viral infections (e.g., norovirus, astrovirus) can lead to chronic, debilitating diarrhea and wasting, requiring prolonged antiviral strategies, including the use of oral immunoglobulins or targeted antivirals [33, 35, 44].

Vaccination and Passive Immunoprophylaxis

Ultimately, the most effective therapeutic intervention is prevention through vaccination. The success of live attenuated rotavirus vaccines (e.g., Rotarix, RotaTeq) in reducing severe diarrheal disease and mortality in children under five serves as a paradigm for enteric virus vaccine development [27]. These vaccines leverage oral administration to stimulate local mucosal immunity, including virus-specific sIgA in the gut, which is critical for neutralizing the virus at the point of entry [16, 19]. However, vaccine efficacy is lower in low- and middle-income countries (LMICs), likely due to interference from concurrent enteric infections, environmental enteropathy, and a dysbiotic microbiota [27]. Current efforts are focused on improving immunogenicity through novel adjuvants (e.g., immune-stimulating complexes, ISCOMs), delivery systems (e.g., virus-like particles, microspheres), and prime-boost strategies incorporating parenteral dosing [16]. For norovirus, a major cause of outbreaks across all age groups, the development of a vaccine has been hampered by antigenic diversity and the lack of a robust, scalable cell culture system for human strains, although virus-like particle (VLP) vaccines targeting the most prevalent genotypes (GII.4) are in advanced clinical trials [27].

In veterinary medicine, passive immunization via lactogenic immunity remains a cornerstone for protecting neonatal livestock from enteric viral infections, such as rotavirus and coronavirus in calves and piglets. Maternal vaccination to boost specific antibody titers in colostrum and milk is a highly effective strategy, as the newborn gut absorbs these antibodies (predominantly IgG1 in ruminants, IgA in swine) to provide immediate, localized protection before the active immune system matures [16, 17]. For canine enteric coronaviruses (CCoV) and parvoviruses (CPV-2), which cause significant morbidity in puppies, modified-live and inactivated vaccines are widely used, though the emergence of recombinant CCoV strains with altered tropism and increased virulence necessitates continuous vaccine strain updates [20, 24, 31]. The development of broadly protective vaccines that can account for the genetic diversity of enteric viruses, particularly for coronaviruses and noroviruses, is an ongoing challenge that requires a deeper understanding of cross-protective epitopes and the role of transkingdom interactions in shaping the host immune response [30].

Vaccination Strategies and Immunoprophylaxis

The development of effective vaccination strategies and immunoprophylactic interventions against viral enteric infections represents one of the most formidable challenges in contemporary veterinary and human medicine. The gastrointestinal tract presents a uniquely complex immunological landscape, where the host immune system must maintain tolerance to commensal microbiota and dietary antigens while mounting robust protective responses against enteric pathogens. This section provides an exhaustive analysis of the current state, mechanistic underpinnings, and future directions of vaccination and immunoprophylaxis for enteric viral infections, drawing upon the latest research across multiple host species and viral families.

The Immunological Basis for Mucosal Vaccination

The cornerstone of effective immunoprophylaxis against enteric viruses lies in the induction of robust mucosal immunity, particularly secretory immunoglobulin A (sIgA) responses within the intestinal lumen. As established in seminal work on porcine enteric coronaviruses, enteropathogenic viruses such as transmissible gastroenteritis virus (TGEV) and rotavirus replicate exclusively within villous enterocytes, making the stimulation of local intestinal immune responses an absolute prerequisite for protection [16]. The challenge, however, is profound: oral administration of soluble or killed antigens typically induces either short-lived immunity or, paradoxically, systemic tolerance [16]. This immunological conundrum has driven decades of research into novel delivery systems and adjuvants capable of overcoming the gut’s inherent tolerogenic bias.

The molecular mechanisms governing this compartmentalized immunity are now being elucidated at an unprecedented resolution. The intestinal epithelium is equipped with a specialized interferon system in which epithelial cells respond primarily to type III interferons (IFN-λ), while hematopoietic cells in the lamina propria rely on type I interferons (IFN-α/β) for antiviral defense [18]. This compartmentalization has profound implications for vaccine design: vaccines that effectively induce IFN-λ responses in intestinal epithelial cells may provide superior protection against enteric viruses compared to those that primarily stimulate systemic IFN-α/β pathways. Indeed, IFN-λ has emerged as a potent regulator of intestinal viral infections, controlling multiple enteric viruses including rotavirus, reovirus, and norovirus, and recombinant IFN-λ holds therapeutic potential against infections that lack other effective treatments [13]. The recognition that IFN-λ receptor deficiency in suckling mice permits reovirus to infect not only gut epithelium but also bile duct epithelial cells underscores the critical role of this cytokine in protecting epithelial barriers during early development [18].

Rotavirus Vaccines: Successes, Limitations, and Emerging Challenges

Rotavirus vaccination represents the most significant success story in enteric viral immunoprophylaxis to date. Currently licensed vaccines, including live attenuated oral formulations, have substantially reduced the global burden of severe rotavirus gastroenteritis in children under five years of age [27]. However, the efficacy of these vaccines in low- and middle-income countries (LMICs) remains suboptimal compared to high-income settings, a disparity that has been attributed to several factors including interference from concurrent enteric infections, malnutrition, and differences in gut microbiota composition [27]. The World Health Organization (WHO) continues to recommend rotavirus vaccination as a priority for national immunization programs worldwide, recognizing that even moderately efficacious vaccines confer substantial public health benefits in settings with high rotavirus mortality.

The mechanisms by which rotavirus vaccines induce protection are multifaceted and incompletely understood. Studies using macrophage-augmented intestinal organoids (MaugOs) have demonstrated that rotavirus efficiently propagates in these systems and stimulates host antiviral responses, providing a powerful platform for dissecting vaccine-induced immunity [3]. Importantly, rotavirus triggers inflammatory responses in MaugOs, suggesting that vaccine strains must be carefully attenuated to balance immunogenicity with reactogenicity [3]. The observation that microbial metabolites such as acetate can potently inhibit virus-induced inflammatory responses while differentially affecting viral replication in macrophages versus organoids [3] opens new avenues for designing vaccine adjuvants that modulate the inflammatory milieu without compromising protective immunity.

Norovirus Vaccines: Navigating Antigenic Diversity and Immune Evasion

The development of effective norovirus vaccines has proven extraordinarily challenging due to the extreme antigenic diversity of these pathogens and their sophisticated immune evasion strategies. Noroviruses of genogroup I (NoV GI) and NoV GII are the primary causes of acute gastroenteritis in developed countries, with NoV GII.4 strains undergoing periodic antigenic drift that necessitates continuous vaccine strain updates [8, 28]. The epidemiological significance of norovirus is underscored by wastewater-based epidemiology studies in Japan, which estimated that NoV GII infections reach 11,997 per 100,000 population during winter-spring seasons, exceeding reported clinical cases by nearly 24-fold [8]. This massive burden of infection, much of which goes undetected, highlights the urgent need for effective vaccines.

A particularly vexing obstacle to norovirus vaccine development is the capacity of these viruses to establish persistent infections with active viral shedding in healthy humans, a phenomenon that appears to involve immune evasion through sequestration in immune-privileged enteric niches. Studies using murine norovirus (MNV) models have revealed that chronic infection drives virus-specific CD8+ tissue-resident memory (Trm) T cells to a differentiation state resembling inflationary effector responses against latent cytomegalovirus, with these cells remaining highly functional yet apparently ignorant of ongoing viral replication [29]. Pre-existing MNV-specific Trm cells provide only partial protection against chronic infection and largely cease to detect virus within 72 hours of challenge, indicating rapid sequestration of viral replication away from T cell surveillance [29]. This discovery of an immune-privileged enteric niche has profound implications for vaccine design, suggesting that vaccines must induce immune responses capable of accessing these protected sites.

The role of secretory immunoglobulins in norovirus infection is equally complex and counterintuitive. Contrary to the expectation that sIgA would provide protective immunity, studies in polymeric immunoglobulin receptor (pIgR) knockout mice revealed that natural sIg are not protective during enteric virus infection but instead promote infection through alterations in microbial immune responses [9]. Lack of pIgR resulted in increased IFN-γ levels, which contributed to reduced MNV titers, and similar effects were observed with reovirus [9]. These findings challenge the conventional paradigm that mucosal antibodies are universally protective and suggest that vaccine strategies aimed at inducing high-titer sIgA responses may need to be reconsidered for certain enteric viruses.

Coronavirus Vaccines for Enteric Disease: Lessons from Companion Animals and Livestock

The emergence of highly pathogenic coronaviruses has galvanized research into vaccines for enteric coronavirus infections across multiple species. Canine enteric coronavirus (CCoV), an alphacoronavirus closely related to feline and porcine enteric coronaviruses, has traditionally caused mild gastrointestinal disease but is now recognized as an emerging infectious disease of dogs, with increasing reports of lethal infections involving both gastrointestinal and systemic viral dissemination [20]. The emergence of novel recombinant CCoV variants containing spike protein N-terminal domains derived from feline and porcine strains [20] underscores the capacity of coronaviruses for rapid genetic change and the need for vaccines that provide broad protection against diverse strains.

Feline enteric coronavirus (FECV) presents a particularly challenging vaccination scenario because of its propensity to mutate into the lethal feline infectious peritonitis virus (FIPV). Experimental FECV infection studies have revealed an aberrant infection pattern in which virus can infect immune cells even in the absence of intestinal replication, with gradual adaptation to these cells allowing non-enterotropic mutants to arise [32]. This finding raises the hypothesis that vaccination strategies aimed at preventing intestinal replication may be insufficient to prevent the emergence of FIPV-causing mutants, and that vaccines must also target systemic immune compartments. The World Organisation for Animal Health (WOAH) recognizes feline coronavirus as a significant pathogen of domestic cats, and ongoing research into FECV vaccines remains a priority for feline medicine.

The Microbiota-Vaccine Axis: Transkingdom Interactions in Immunoprophylaxis

Perhaps the most transformative insight to emerge from recent research is the recognition that the intestinal microbiota profoundly shapes vaccine responses against enteric viruses. The bacterial microbiome fosters enteric viral persistence in a manner counteracted by specific components of the innate immune system, with antibiotics preventing persistent MNV infection through mechanisms requiring IFN-λ receptor signaling [33]. This finding has direct implications for vaccination: the composition of an individual’s gut microbiota may determine the magnitude and quality of vaccine-induced immune responses, potentially explaining the reduced efficacy of oral rotavirus vaccines in LMICs where gut microbiota composition differs substantially from that in high-income countries.

The molecular mechanisms underlying microbiota-mediated modulation of antiviral immunity are being progressively unraveled. Ginsenoside Rg3, an herbal monomer, shapes the gut microbiota by enriching short-chain fatty acid (SCFA)-producing Blautia species, which protect against enteric virus infection by inducing type I interferon responses in macrophages via the MAVS-IRF3-IFNAR signaling pathway [34]. Exogenous SCFAs (acetate/propionate) reproduce this protective effect by enhancing intracellular Ca²⁺- and MAVS-dependent mtDNA release, activating the cGAS-STING-IFN-I axis through GPR43 signaling in macrophages [34]. These findings suggest that vaccine adjuvants designed to mimic or enhance SCFA signaling could potentiate antiviral immune responses, particularly in individuals with suboptimal microbiota composition.

The influence of microbiota-derived metabolites extends beyond SCFAs to include flavonoids and bile acids, which generally regulate interferon responses [36]. A common theme emerging from this research is that microbiota-derived metabolites can have both proviral and antiviral effects depending on the specific virus in question [36], indicating that vaccine strategies must be tailored to the particular pathogen and host context. The demonstration that enteric helminth infection can have remote protective antiviral effects in the lung through induction of a microbiota-dependent type I interferon response [49] further illustrates the complex transkingdom interactions that shape antiviral immunity and suggests that modulation of the microbiome could be exploited to enhance vaccine efficacy at distant mucosal sites.

Novel Vaccine Platforms and Delivery Systems

The limitations of traditional live attenuated and inactivated vaccines for enteric viruses have spurred development of innovative platforms. Single-domain antibodies (sdAbs) derived from camelid heavy-chain antibodies offer unique advantages for passive immunoprophylaxis, including small size enabling access to cryptic epitopes, relatively low production costs, and improved robustness [48]. While no sdAbs have been approved for clinical use against viral infections, their development against enteric viruses including norovirus and rotavirus represents a promising avenue for therapeutic intervention [48].

The use of virus-like particles (VLPs) and recombinant vectors for oral vaccination has shown promise in preclinical studies. Immune stimulating complexes (ISCOMs), liposomes, and live recombinant vectors such as attenuated Salmonella or Lactobacillus strains have been explored as delivery systems for enteric virus antigens [16]. The demonstration that vesicle-cloaked virus clusters are optimal units for inter-organismal viral transmission, delivering a high inoculum to the receiving host and enhancing both multiplicity of infection and disease severity [23], suggests that vaccine formulations mimicking these natural transmission units could induce more robust immune responses.

Challenges in Vaccine Development for Veterinary Species

The development of effective vaccines for enteric viral infections in livestock and companion animals faces unique challenges related to the timing of infection and the need for passive immunity. In calves, where most viral enteric infections occur within the first three weeks of life, passive lactogenic immunity within the gut lumen plays an essential protective role [17]. Vaccination of pregnant cows with rotavirus vaccines has been shown to elevate rotavirus immunoglobulin G1 antibodies in colostrum and milk, and feeding colostrum from immunized cows to newborn calves prevented diarrhea and shedding of rotavirus [17]. However, commercial vaccines show limited efficacy in the field, and only oral vaccines containing live replicating organisms have been highly effective in inducing mucosal immune responses [16].

In swine, transmissible gastroenteritis virus (TGEV) and rotavirus remain significant causes of neonatal diarrhea, and vaccination strategies must overcome the challenge of inducing protective immunity in the face of maternal antibodies [16]. The use of novel mucosal adjuvants, including cholera toxin B subunit, E. coli enterotoxins, and cytokines, has been explored to enhance immune responses to oral vaccines [16]. The Food and Agriculture Organization (FAO) recognizes enteric viral diseases as major constraints to livestock production in developing countries, and improved vaccines are urgently needed.

Future Directions and Unresolved Questions

Despite substantial progress, numerous questions remain regarding optimal vaccination strategies for enteric viruses. The phenomenon of viral co-infections, which are increasingly detected with the use of multiplex PCR assays [2, 6, 12], raises questions about whether multivalent vaccines can induce balanced immune responses against multiple pathogens simultaneously. Co-infections are detected in 8.3% of virus-positive patients with acute gastroenteritis, with rotavirus-norovirus combinations being most common [12], and the impact of these co-infections on vaccine efficacy remains poorly understood.

The role of the enteric nervous system (ENS) in antiviral immunity represents an underexplored frontier. Growing evidence highlights enteric glial cells and the microbiota as important players in gut inflammation and dysfunction following viral infections [5], and it is plausible that the ENS could be targeted by vaccines or immunomodulatory agents to enhance protective responses. The demonstration that influenza virus infection impairs gut barrier properties and favors secondary enteric bacterial infection through reduced production of SCFAs [38] suggests that vaccination against respiratory viruses may have indirect benefits for enteric health, and that SCFA supplementation could be used as an adjunct to vaccination.

The development of vaccines that induce broadly neutralizing antibodies against antigenically diverse enteric viruses remains a major goal. The identification of conserved epitopes on viral surface proteins, combined with structure-based vaccine design, offers hope for universal vaccines against norovirus and rotavirus. The use of human intestinal enteroids and macrophage-augmented organoids [3] provides powerful platforms for testing vaccine candidates and dissecting the mechanisms of protective immunity at the cellular and molecular level. As our understanding of the complex transkingdom interactions that govern enteric viral infections continues to deepen, the prospects for rational design of effective vaccination and immunoprophylaxis strategies have never been greater.

Special Considerations: Viral Enteric Infections in Immunocompromised and Inflammatory Bowel Disease Patients

The intersection of viral enteric infections with immunocompromised states and inflammatory bowel disease (IBD) represents a nexus of complex pathophysiology that challenges conventional paradigms of host-pathogen interaction. Patients with compromised immune systems, whether due to primary immunodeficiencies, pharmacologic immunosuppression, or chronic inflammatory conditions such as Crohn’s disease (CD) and ulcerative colitis (UC), occupy a uniquely vulnerable position wherein enteric viruses can behave in ways fundamentally distinct from their behavior in immunocompetent hosts. The clinical, virologic, and immunologic considerations in these populations extend far beyond simple susceptibility and encompass altered viral kinetics, aberrant immune responses, diagnostic ambiguity, and therapeutic dilemmas that demand specialized clinical acumen.

Altered Viral Dynamics in the Immunocompromised Intestine

The intestinal epithelium of immunocompromised patients represents a profoundly altered landscape for enteric virus replication and persistence. In hematopoietic stem cell transplant recipients, solid organ transplant patients, and those receiving biologic therapies (particularly anti-TNFα agents, integrin antagonists, and JAK inhibitors), the delicate balance between viral clearance and immune-mediated tissue damage is disrupted. This disruption manifests in several clinically critical ways. First, the duration of viral shedding is markedly prolonged. While immunocompetent individuals typically clear norovirus, rotavirus, or adenovirus infections within days to weeks, immunocompromised patients can shed these viruses for months or even years [22, 35]. This prolonged shedding has dual consequences: it increases the reservoir for nosocomial and community transmission, particularly within oncology wards and transplant units, and it amplifies the opportunity for viral evolution, including the emergence of antigenic variants that may escape population-level immunity.

The mechanisms underlying this persistence are multifaceted. The type III interferon (IFN-λ) system, which constitutes the primary antiviral defense at mucosal surfaces, is exquisitely sensitive to perturbations in immune competence. Unlike type I interferons (IFN-α/β), which act systemically, IFN-λ signals almost exclusively on epithelial cells, making it the frontline defender against enteric viral invasion [13, 18, 26]. In immunocompromised hosts, the production of and responsiveness to IFN-λ can be severely impaired. This is particularly relevant in the context of biologic therapies that target cytokine signaling pathways. For instance, JAK inhibitors, increasingly used in refractory IBD, block downstream signaling from multiple cytokine receptors, including those for IFN-λ, thereby crippling the epithelial antiviral response [22, 35]. The compartmentalized nature of the intestinal interferon system, where epithelial cells rely primarily on IFN-λ while lamina propria cells depend on type I IFNs, means that disruption of one arm can create permissive niches for viral replication even when the other arm remains functional [18, 26].

The Paradox of Secretory IgA and Antimicrobial Peptides in Immunocompromised States

One of the most counterintuitive findings in enteric virology pertains to the role of secretory immunoglobulins (sIg) in the immunocompromised gut. Conventional wisdom holds that sIgA and sIgM, transported into the intestinal lumen via the polymeric immunoglobulin receptor (pIgR), provide essential immune exclusion and neutralization of enteric pathogens. However, elegant studies using murine models have revealed that natural sIg can paradoxically promote enteric viral infections. In pIgR knockout mice, which lack sIg in mucosal secretions, murine norovirus (MNV) titers are significantly reduced compared to wild-type controls [9]. This proviral effect is mediated through sIg-dependent alterations in the intestinal microbiota and the ensuing immune milieu. Specifically, the absence of sIg leads to enhanced levels of IFN-γ in the ileum, which in turn suppresses viral replication. When the microbiota is depleted with antibiotics, this difference between pIgR-deficient and wild-type mice is abolished, indicating that sIg exerts its proviral effects via microbial sensing pathways [9].

This finding has profound implications for immunocompromised patients who may have quantitative or qualitative deficiencies in secretory immunoglobulins. Patients with common variable immunodeficiency (CVID), for example, frequently have low or absent sIgA and are paradoxically at increased risk for chronic enteric viral infections. The mechanism may involve not simply the loss of immune exclusion, but rather the disruption of a complex regulatory circuit wherein sIg normally dampens IFN-γ production through interactions with the microbiota. When sIg is absent, the unrestrained IFN-γ response may actually be protective in some contexts, but this comes at the cost of chronic inflammation, a trade-off that is particularly problematic in patients with concomitant IBD.

Similarly, enteric α-defensins, antimicrobial peptides produced abundantly by Paneth cells in the small intestine, exhibit a dual role that is magnified in immunocompromised states. While these defensins are classically considered antiviral, studies using primary stem cell-derived enteroids have demonstrated that mouse adenovirus 2 (MAdV-2) infection is actually enhanced across an α-defensin gradient, mimicking oral infection [37]. This enhancement occurs through receptor-independent binding of virus to the cell surface. In mice lacking functional α-defensins, fecal viral shedding is reduced. The evolutionary implications are sobering: some enteric viruses may have evolved to co-opt these host defense molecules to facilitate their own infection. In immunocompromised patients, where defensin expression may be dysregulated by inflammation, antibiotics, or nutritional deficiencies, this proviral mechanism could be amplified.

The Microbiota-Virome Axis in IBD and Immunosuppression

Inflammatory bowel disease represents a particularly complex environment for enteric viral infections because the disease itself is characterized by dysbiosis of the bacterial microbiota, altered mucus barrier function, and chronic immune activation. The gut microbiota exerts profound effects on enteric virus infections through multiple mechanisms, including direct binding to viral particles, modulation of the host interferon response, and production of metabolites that influence viral replication [7, 30]. In IBD patients, the composition of the bacterial microbiota is markedly altered, with reduced diversity, depletion of short-chain fatty acid (SCFA)-producing bacteria such as Blautia and Faecalibacterium, and blooms of potentially pathogenic taxa [22, 30]. These changes have direct consequences for enteric virus susceptibility.

Short-chain fatty acids, particularly acetate, propionate, and butyrate, are microbial metabolites that play critical roles in maintaining intestinal barrier integrity and modulating immune responses. Acetate has been shown to potently inhibit virus-induced inflammatory responses in macrophage-augmented intestinal organoids while differentially affecting viral replication in macrophages versus epithelial cells [3]. The mechanism involves GPR43 signaling in macrophages, which enhances intracellular calcium-dependent mitochondrial DNA release and activates the cGAS-STING-IFN-I axis [34]. In IBD patients, the depletion of SCFA-producing commensals may therefore impair this antiviral signaling pathway, rendering the epithelium more permissive to viral infection. Conversely, supplementation with SCFAs or with probiotic strains that produce them (such as Blautia coccoides and Blautia obeum) has been shown to protect against enteric virus infection in experimental models by inducing IFN-I responses [34].

The virome itself, the collection of viruses inhabiting the gut, undergoes dramatic shifts in IBD. Metagenomic studies have revealed expansion of enteric viruses, particularly bacteriophages, in IBD patients, but the implications for pathogenic enteric virus infection remain incompletely understood. Intriguingly, there is evidence that components of the virome can complement immunodeficiency. In a landmark study, murine astrovirus was shown to protect immunodeficient mice against norovirus and rotavirus infection through an IFN-λ-dependent mechanism [11]. This protection was horizontally transferable via co-housing and fecal transplantation. Such findings raise the possibility that the virome of IBD or immunocompromised patients, which may be altered by antibiotics, immunosuppressants, and disease activity, could influence susceptibility to pathogenic enteric viruses in ways that are currently unpredictable.

Clinical Implications: Diagnostic Challenges and Therapeutic Considerations

The diagnosis of viral enteric infections in immunocompromised and IBD patients is fraught with interpretive difficulty. Multiplex PCR panels, while highly sensitive, detect viral nucleic acids that may represent active infection, prolonged shedding from a prior infection, or even asymptomatic carriage. In a retrospective study of acute severe UC patients, 14.9% tested positive for adenovirus 40/41, rotavirus, or norovirus GI by faecal multiplex PCR, yet these infections did not affect admission C-reactive protein, endoscopic severity, length of stay, need for rescue therapy, or colectomy rate [1]. This finding suggests that in the context of acute severe colitis, detection of these common viral enteropathogens may be incidental to the disease flare rather than causative. The implication is critical: treating a detected virus in a decompensating IBD patient with antiviral therapy may be unnecessary and could delay appropriate escalation of immunosuppression.

However, this conclusion may not apply to all viruses or all patient populations. Cytomegalovirus (CMV) infection in steroid-refractory UC is a well-established indication for antiviral therapy, and the distinction between CMV and other enteric viruses underscores the need for virus-specific risk stratification [35]. For norovirus in particular, chronic infections in immunocompromised hosts can cause protracted diarrhea, weight loss, and malnutrition that significantly impact quality of life and transplant outcomes. The use of nitazoxanide, oral immunoglobulins, or ribavirin has been reported in case series with variable success, but no standardized treatment guidelines exist.

Therapeutic considerations must also account for the potential of enteric viral infections to trigger or exacerbate IBD flares. Genome-wide association studies have linked polymorphisms in FUT2 and FUT3, genes encoding fucosyltransferases that synthesize histo-blood group antigens serving as ligands for norovirus and rotavirus, with IBD susceptibility [22]. This genetic connection suggests a mechanistic link between enteric virus binding and IBD pathogenesis. Furthermore, enteric virus interactions with Paneth cells, which are dysfunctional in many IBD patients due to autophagy gene polymorphisms (e.g., ATG16L1), could amplify inflammation. Norovirus infection in mice with Paneth cell defects triggers excessive TNFα production and intestinal pathology that mirrors aspects of human IBD [22].

Special Populations: HIV/AIDS and Transplant Recipients

In patients with advanced HIV/AIDS, enteric viral infections were historically a major cause of chronic diarrhea and wasting. With the advent of effective antiretroviral therapy, the incidence has declined, but these infections remain clinically important in patients with poor virologic control or those who are antiretroviral-naïve. The spectrum of pathogens includes not only CMV but also adenovirus, rotavirus, astrovirus, and caliciviruses (norovirus and sapovirus) [44]. In these patients, the absence of CD4+ T cell help cripples adaptive immune responses, making viral clearance dependent almost entirely on innate mechanisms, including IFN-λ and natural killer cells. The chronic inflammation associated with HIV infection, even when virally suppressed, may further alter the intestinal microenvironment in ways that promote enteric virus persistence.

Transplant recipients, particularly those undergoing intestinal or multivisceral transplantation, represent the extreme end of the immunocompromised spectrum. The combination of potent immunosuppression (typically including calcineurin inhibitors, antiproliferative agents, and corticosteroids) with surgical disruption of the enteric nervous system and lymphatic drainage creates a uniquely permissive environment for enteric viruses [5]. Norovirus outbreaks in transplant wards are notoriously difficult to control, as standard infection prevention measures, hand hygiene, contact precautions, environmental disinfection, are often insufficient to prevent transmission from patients who shed virus for extended periods. The use of wastewater-based epidemiology has demonstrated that norovirus and other enteric viruses circulate silently in communities at levels far exceeding those captured by clinical surveillance [8, 42], and this background circulation poses a constant threat to immunocompromised patients.

Emerging Therapeutic Horizons

Advances in our understanding of enteric virus-host interactions at mucosal surfaces are opening new therapeutic avenues for immunocompromised patients. Recombinant IFN-λ has shown promise in clinical trials for hepatitis D and in preclinical models for norovirus and rotavirus, offering the advantage of targeted epithelial activity without the systemic inflammation associated with type I IFNs [13, 26]. Single-domain antibodies (nanobodies) against enteric viruses are being developed that could be delivered orally to neutralize viruses in the gut lumen [48]. Macrophage-augmented organoids (MaugOs) that recapitulate the complex immune-epithelial interactions of the infected intestine are enabling high-throughput screening of combination therapies that simultaneously target viral replication and host inflammatory responses [3]. The demonstration that acetate and other SCFAs can inhibit virus-induced inflammation while differentially affecting viral replication in macrophages versus organoids [3] highlights the potential for metabolite-based therapies that restore the protective functions of the depleted microbiota in IBD and immunocompromised patients.

The tripartite relationship between the host immune system, the gut microbiota, and enteric viruses is now recognized as a central determinant of infection outcome in vulnerable populations. As our understanding of transkingdom interactions deepens, the development of therapies that modulate the microbial environment, whether through prebiotics, probiotics, fecal microbiota transplantation, or targeted antimicrobials, may offer complementary strategies to direct antiviral agents in protecting immunocompromised and IBD patients from the substantial morbidity associated with viral enteric infections [30, 33].

References

[1] Ostrowski S, Croft A. Viral enteric infections in acute severe ulcerative colitis.. Journal of Crohn's & Colitis. 2022. DOI: https://doi.org/10.1093/ecco-jcc/jjac028

[2] Deng X, Zhang J, Su J, Liu H, Cong Y, Zhang L, et al.. A multiplex PCR method for the simultaneous detection of three viruses associated with canine viral enteric infections. Archives of Virology. 2018. DOI: https://doi.org/10.1007/s00705-018-3828-4

[3] Xu G, Zhou J, Liu K, Wang Y, Tsikari T, Qin F, et al.. Macrophage-augmented intestinal organoids model virus-host interactions in enteric viral diseases and facilitate therapeutic development. Nature Communications. 2025. DOI: https://doi.org/10.1038/s41467-025-59639-9

[4] Mochizuki M, Hashimoto M, Ishida T. Recent epidemiological status of canine viral enteric infections and Giardia infection in Japan.. Journal of Veterinary Medical Science. 2001. DOI: https://doi.org/10.1292/JVMS.63.573

[5] Valdetaro L, Thomasi B, Ricciardi MC, Santos KdM, Coelho-Aguiar JM, Tavares-Gomes AL. Enteric nervous system as a target and source of SARS-CoV-2 and other viral infections. American Journal of Physiology - Gastrointestinal and Liver Physiology. 2023. DOI: https://doi.org/10.1152/ajpgi.00229.2022

[6] Makimaa H, Ingle H, Baldridge MT. Enteric Viral Co-Infections: Pathogenesis and Perspective. Viruses. 2020. DOI: https://doi.org/10.3390/v12080904

[7] Segrist E, Cherry S. Using Diverse Model Systems to Define Intestinal Epithelial Defenses to Enteric Viral Infections. Cell Host and Microbe. 2020. DOI: https://doi.org/10.1016/j.chom.2020.02.003

[8] Shrestha S, Malla B, Haramoto E. Estimation of Norovirus infections in Japan: An application of wastewater-based epidemiology for enteric disease assessment.. Science of the Total Environment. 2023. DOI: https://doi.org/10.1016/j.scitotenv.2023.169334

[9] Turula H, Cunha JB, Mainou BA, Ramakrishnan S, Wilke C, González-Hernández M, et al.. Natural Secretory Immunoglobulins Promote Enteric Viral Infections. Journal of Virology. 2018. DOI: https://doi.org/10.1128/JVI.00826-18

[10] Martella V, Decaro N, Buonavoglia C. Enteric viral infections in lambs or kids. Veterinary Microbiology. 2015. DOI: https://doi.org/10.1016/j.vetmic.2015.08.006

[11] Ingle H, Lee S, Ai TL, Orvedahl A, Rodgers R, Zhao G, et al.. Viral complementation of immunodeficiency confers protection against enteric pathogens via IFN-λ. Nature Microbiology. 2019. DOI: https://doi.org/10.1038/s41564-019-0416-7

[12] Grazia SD, Bonura F, Bonura C, Mangiaracina L, Filizzolo C, Martella V, et al.. Assessing the burden of viral co-infections in acute gastroenteritis in children: An eleven-year-long investigation.. Journal of Clinical Virology. 2020. DOI: https://doi.org/10.1016/j.jcv.2020.104513

[13] Lee S, Baldridge MT. Interferon-Lambda: A Potent Regulator of Intestinal Viral Infections. Frontiers in Immunology. 2017. DOI: https://doi.org/10.3389/fimmu.2017.00749

[14] Mansour A, Koutby ME, Barbary MEE, Mohamed W, Shehata S, Mohammady HE, et al.. Enteric viral infections as potential risk factors for intussusception.. Journal of Infection in Developing Countries. 2013. DOI: https://doi.org/10.3855/jidc.2321

[15] Wang J, Wang L, Lu W, Farhataziz N, Gonzalez A, Xing J, et al.. TRIM29 controls enteric RNA virus-induced intestinal inflammation by targeting NLRP6 and NLRP9b signaling pathways. Mucosal Immunology. 2024. DOI: https://doi.org/10.1016/j.mucimm.2024.10.004

[16] Saif L. Enteric Viral Infections of Pigs and Strategies for Induction of Mucosal Immunity. Advances in Veterinary Medicine. 1999. DOI: https://doi.org/10.1016/S0065-3519(99)80033-0

[17] Saif L, Smith K. Enteric Viral Infections of Calves and Passive Immunity. Journal of Dairy Science. 1985. DOI: https://doi.org/10.3168/jds.S0022-0302(85)80813-4

[18] Mahlakõiv T, Hernández PP, Gronke K, Diefenbach A, Staeheli P. Leukocyte-Derived IFN-α/β and Epithelial IFN-λ Constitute a Compartmentalized Mucosal Defense System that Restricts Enteric Virus Infections. PLoS Pathogens. 2015. DOI: https://doi.org/10.1371/journal.ppat.1004782

[19] Lockhart A, Mucida D, Parsa R. Immunity to enteric viruses. Immunity. 2022. DOI: https://doi.org/10.1016/j.immuni.2022.04.007

[20] Licitra BN, Duhamel G, Whittaker G. Canine Enteric Coronaviruses: Emerging Viral Pathogens with Distinct Recombinant Spike Proteins. Viruses. 2014. DOI: https://doi.org/10.3390/v6083363

[21] Lanrewaju AA, Enitan-Folami A, Sabiu S, Edokpayi J, Swalaha F. Global public health implications of human exposure to viral contaminated water. Frontiers in Microbiology. 2022. DOI: https://doi.org/10.3389/fmicb.2022.981896

[22] Tarris G, Rougemont Ad, Charkaoui M, Michiels C, Martin L, Belliot G. Enteric Viruses and Inflammatory Bowel Disease. Viruses. 2021. DOI: https://doi.org/10.3390/v13010104

[23] Santiana M, Ghosh S, Ho B, Rajasekaran V, Du W, Mutsafi Y, et al.. Vesicle-cloaked virus clusters are optimal units for inter-organismal viral transmission.. Cell Host and Microbe. 2018. DOI: https://doi.org/10.1016/j.chom.2018.07.006

[24] Haake CJE, Cook SE, Pusterla N, Murphy B. Coronavirus Infections in Companion Animals: Virology, Epidemiology, Clinical and Pathologic Features. Viruses. 2020. DOI: https://doi.org/10.3390/v12091023

[25] Hao X, Liu R, He Y, Xiao X, Xiao W, Zheng Q, et al.. Multiplex PCR methods for detection of several viruses associated with canine respiratory and enteric diseases. PLoS ONE. 2019. DOI: https://doi.org/10.1371/journal.pone.0213295

[26] Ingle H, Peterson ST, Baldridge MT. Distinct Effects of Type I and III Interferons on Enteric Viruses. Viruses. 2018. DOI: https://doi.org/10.3390/v10010046

[27] Riddle MS, Chen WH, Kirkwood C, MacLennan C, MacLennan C. Update on vaccines for enteric pathogens.. Clinical Microbiology and Infection. 2018. DOI: https://doi.org/10.1016/j.cmi.2018.06.023

[28] Cho S, Chae S, Jung S, Choi W, Han M, Yoo C, et al.. Trends in acute viral gastroenteritis among children aged ≤5 years through the national surveillance system in South Korea, 2013–2019. Journal of Medical Virology. 2020. DOI: https://doi.org/10.1002/jmv.26685

[29] Tomov V, Palko O, Lau C, Pattekar A, Sun Y, Tacheva R, et al.. Differentiation and protective capacity of virus-specific CD8+ T cells suggest murine norovirus persistence in an immune-privileged enteric niche. Immunity. 2017. DOI: https://doi.org/10.1016/j.immuni.2017.09.017

[30] Pfeiffer JK, Virgin H. Transkingdom control of viral infection and immunity in the mammalian intestine. Science. 2016. DOI: https://doi.org/10.1126/science.aad5872

[31] Dowgier G, Lorusso E, Decaro N, Desario C, Mari V, Lucente M, et al.. A molecular survey for selected viral enteropathogens revealed a limited role of Canine circovirus in the development of canine acute gastroenteritis. Veterinary Microbiology. 2017. DOI: https://doi.org/10.1016/j.vetmic.2017.04.007

[32] Desmarets L, Vermeulen B, Theuns S, Conceição-Neto N, Zeller M, Roukaerts IDM, et al.. Experimental feline enteric coronavirus infection reveals an aberrant infection pattern and shedding of mutants with impaired infectivity in enterocyte cultures. Scientific Reports. 2016. DOI: https://doi.org/10.1038/srep20022

[33] Baldridge MT, Nice TJ, McCune B, Yokoyama CC, Kambal A, Wheadon MJ, et al.. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection. Science. 2014. DOI: https://doi.org/10.1126/science.1258025

[34] Wang G, Liu J, Zhang Y, Xie J, Chen S, Shi Y, et al.. Ginsenoside Rg3 enriches SCFA-producing commensal bacteria to confer protection against enteric viral infection via the cGAS-STING-type I IFN axis. The ISME Journal. 2023. DOI: https://doi.org/10.1038/s41396-023-01541-7

[35] Dehghani T, Gholizadeh O, Daneshvar M, Nemati MM, Akbarzadeh S, Amini P, et al.. Association Between Inflammatory Bowel Disease and Viral Infections. Current Microbiology. 2023. DOI: https://doi.org/10.1007/s00284-023-03305-0

[36] Alwin A, Karst SM. The influence of microbiota-derived metabolites on viral infections. Current Opinion in Virology. 2021. DOI: https://doi.org/10.1016/j.coviro.2021.05.006

[37] Wilson SS, Bromme BA, Holly MK, Wiens ME, Gounder A, Sul Y, et al.. Alpha-defensin-dependent enhancement of enteric viral infection. PLoS Pathogens. 2017. DOI: https://doi.org/10.1371/journal.ppat.1006446

[38] Sencio V, Gallerand A, Machado MG, Deruyter L, Heumel S, Soulard D, et al.. Influenza Virus Infection Impairs the Gut’s Barrier Properties and Favors Secondary Enteric Bacterial Infection through Reduced Production of Short-Chain Fatty Acids. Infection and Immunity. 2021. DOI: https://doi.org/10.1128/IAI.00734-20

[39] Cortez V, Schultz‐Cherry S. The role of goblet cells in viral pathogenesis. The FEBS Journal. 2020. DOI: https://doi.org/10.1111/febs.15731

[40] Johnson BA, Hage A, Kalveram BK, Mears MC, Plante JA, Rodriguez SE, et al.. Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.01282-19

[41] Wang L, Han J, Zhou S, Yu L, Lu Q, Zhang X, et al.. The changing pattern of enteric pathogen infections in China during the COVID-19 pandemic: a nation-wide observational study. The Lancet Regional Health - Western Pacific. 2021. DOI: https://doi.org/10.1016/j.lanwpc.2021.100268

[42] Bisseux M, Colombet J, Mirand A, Roque-Afonso A, Abravanel F, Izopet J, et al.. Monitoring human enteric viruses in wastewater and relevance to infections encountered in the clinical setting: a one-year experiment in central France, 2014 to 2015. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2018. DOI: https://doi.org/10.2807/1560-7917.ES.2018.23.7.17-00237

[43] Bing-Yuan, Zhang Y, Leung NHL, Cowling B, Yang Z. Role of viral bioaerosols in nosocomial infections and measures for prevention and control. Journal of Aerosol Science. 2017. DOI: https://doi.org/10.1016/j.jaerosci.2017.11.011

[44] Thomas P, Pollok R, Gazzard B. Enteric viral infections as a cause of diarrhoea in the acquired immunodeficiency syndrome. HIV Medicine. 1999. DOI: https://doi.org/10.1046/j.1468-1293.1999.00004.x

[45] Kerr P, Donnelly T. Viral Infections of Rabbits. Veterinary Clinics of North America Exotic Animal Practice. 2013. DOI: https://doi.org/10.1016/j.cvex.2013.02.002

[46] Vilcu A, Sabatte L, Blanchon T, Souty C, Maravic M, Lemaitre M, et al.. Association Between Acute Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses. JAMA Network Open. 2019. DOI: https://doi.org/10.1001/jamanetworkopen.2019.16205

[47] Yildiz S, Mazel-Sanchez B, Kandasamy M, Manicassamy B, Schmolke M. Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis. Microbiome. 2018. DOI: https://doi.org/10.1186/s40168-017-0386-z

[48] Wu Y, Jiang S, Ying T. Single-Domain Antibodies As Therapeutics against Human Viral Diseases. Frontiers in Immunology. 2017. DOI: https://doi.org/10.3389/fimmu.2017.01802

[49] McFarlane A, McSorley H, Davidson D, Fitch P, Wilson C, Mackenzie K, et al.. Enteric helminth-induced type-I interferon signalling protects against pulmonary virus infection through interaction with microbiota. Journal of Allergy and Clinical Immunology. 2017. DOI: https://doi.org/10.1016/j.jaci.2017.01.016